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Multiple inflammatory disease states are marked by disturbances in coagulation. 
Coagulation is the biological process initiated from activation of two independent enzymatic 
pathways, which join to a common pathway, to produce the matrix component of blood clots. 
Tissue factor initiates extrinsic coagulation when damaged endothelial cells interact with 
circulating blood plasma, while factor XII initiates the contact pathway upon interaction with an 
anionic surface. Factor XIIa, the activated form, proceeds to activate factor XI and drive intrinsic 
coagulation. Additionally, factor XIIa activates prekallikrein, driving the inflammatory contact 
system. High molecular weight kininogen is a cofactor for intrinsic coagulation and the contact 
system; kininogen facilitates localization factor XI or prekallikrein, respectively, to the same 
surface as factor XII. Once prekallikrein is activated to kallikrein, it cleaves kininogen to release 
the inflammatory peptide bradykinin. While inhibition of the extrinsic coagulation pathway may 
limit the pathological clotting (thrombosis), it increases the risk of bleeding. However, inhibition 
of factor XII has been demonstrated to prevent thrombosis while not producing the same 
bleeding risk. We anticipate that genetic deficiency of high molecular weight kininogen would 
confer protection in animal models of these disease states. Moreover, we believe that cleaved 
kininogen in plasma from human patients could serve as an indicator of inflammation, or a 
biomarker for disease severity.  
First, I recapitulated enzyme linked immunosorbent assays (ELISAs) which detect 
enzyme:inhibitor complexes from human plasma, as an indicator of contact system activation. 
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These assays are sensitive, and specific, at percentages near that of a typical clinical assay. 
Second, kininogen-deficient mice examined for disease severity. In an acetaminophen-induced 
liver injury model, kininogen-deficient mice exhibited significantly less liver injury within the first 
24 hours, as indicated by liver histology and circulating biomarkers of hepatotoxicity. Third, 
human patient plasmas from acute liver failure were analyzed for the circulating concentration of 
cleaved kininogen. In acute liver failure, while circulating cleaved kininogen was significantly 
higher than that of normal controls, it did not correlate with increased likelihood of death. Finally, 
we identified that plasmin, the terminal enzyme in the clot dissolution pathway (fibrinolysis), can 
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CHAPTER 1: INTRODUCTION 
1.1 Blood coagulation; the extrinsic, intrinsic, and fibrinolytic pathways 
Coagulation is the biological process of fluid blood becoming more gelatinous to stop 
blood loss as a component of the hemostasis mechanism. Along with activation, adhesion, and 
aggregation of platelets, the hemostatic process involves a proteolytic cascade of enzymes 
designed to produce a network of the polymerized protein fibrin (1,2). Fibrin is generated from 
the soluble protein fibrinogen when thrombin, the terminal enzyme in that enzymatic cascade, 
cleaves fibrinogen into fibrin monomers. These monomers are crosslinked to form the fibrin 
network, which entraps the platelets by forming an insoluble framework that maintains clot 
stability during platelet contraction.  
Thrombin generation can be initiated by two independent pathways, extrinsic and 
intrinsic coagulation, which both continue down a common pathway of coagulation (Figure 1.1). 
The intrinsic pathway, also known as the contact system (CS), begins when factor (F) XII comes 
into contact with a negatively charged surface, and autoproteolytically activates to become 
FXIIa (3) FXIIa can then cleave FXI into its active form, FXIa. FXIa can subsequently cleave FIX 
to generate FIXa. FIXa interacts with its cofactor FVIIIa, to form the intrinsic tenase. This 
complex activates FX to FXa, which proceeds down the common pathway. The extrinsic 
pathway, also known as the tissue factor (TF) pathway, begins when the protein TF becomes 
exposed to the bloodstream (4). As an example. If a blood vessel (endothelium) is damaged, 
circulating FVII interacts with exposed TF on the endothelial surface, forming the active 
TF:FVIIa complex. This complex, along with Ca2+ ion, forms the extrinsic tenase, also activating 
FX to FXa. FXa, and its cofactor FVa form the prothrombinase complex on a phospholipid 
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membrane, which activates prothrombin to become the enzyme thrombin. Thrombin can amplify 
its own activation via backloops in the pathway, as it activates factors FV, FVIII, and FXI (5,6). 
Fibrinolysis is another critical component of the hemostasis mechanism; it acts as the 
balancing component to the coagulation pathways (7). Fibrinolysis is the breakdown of fibrin 
polymer networks by the enzyme plasmin. Plasminogen is the zymogen (proenzyme) precursor 
to plasmin, which circulates in the blood, and integrates into the forming clot. Plasminogen 
docks on the surface of fibrin at lysine residues, where it is predominantly activated by tissue 
plasminogen activator (tPA) (8), though enzymes of the CS have also been demonstrated to 
cleave plasminogen as well (9,10). Plasmin activity produces soluble fibrin degradation 
products, which may be protealytically degraded or cleared by the kidney and liver.  
Enzymes of the hemostatic mechanism are serine proteases, where a serine residue 
acts as the active site electron donor in peptide bond cleavage (11). These enzymes are tightly 
controlled, as dysregulation of nominal coagulation can lead to pathologic clotting (thrombosis) 
or bleeding. Serine protease inhibitors (serpins) are proteins which irreversibly inhibit serine 
proteases by covalently bonding with, and causing a conformational change in the enzymatic 
active site (Figure 1.2) (12). Moreover, serpin deficiencies may cause dysregulation, and 
disease states, independent of enzymatic disorders (13,14). The serpins of the coagulation 
cascade can broadly act as inhibitors. As an example, antithrombin (AT), predominantly inhibits 
thrombin and FXa, but may also inhibit FXI, FXII, tPA, and plasmin (15). Detection of these 
enzyme:serpin complexes in plasma has long provided a valuable assessment of the 
























Figure 1.1: The coagulation cascade. Coagulation may be initiated via two 
independent pathways, intrinsic (blue panel) and extrinsic (teal panel), which both 
continue down a common pathway of coagulation (pink panel). Zymogens are green 
ovals, and enzymes are yellow ovals. Blue arrows indicate enzymatic activity. PL= 






















Figure 1.2: Serpin inhibitory mechanism. Alpha 1 antitrypsin as an example. 
Serpin conformational core is the five strand β sheet (s1A, s2A, s3A, s5A, and s6A). 
RCL= reactive center loop. P1’, P1=enzymatic cleavage site. Following cleavage at 
the enzymatic site, the SERPIN refolds so that a segment of the cleaved RCL is 
inserted between central β-sheet A. This conformational change covalently links the 
protease, and renders it inactive. Modified from (12). 
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1.2 Acute liver failure, a focus on acetaminophen toxicity 
Acute liver failure (ALF) is a rare, but highly morbid condition. In the industrialized world, 
the incidence is less than 10 cases per million people annually (19,20). ALF is the consequence 
of abrupt hepatocellular injury or death, which may progress acutely (3-28 days), hyper-acutely 
(hours-2 days), or sub-acutely (4-12 weeks) to a life-threatening condition. The hallmark 
complications are hepatic encephalopathy and coagulopathy, though disease may proceed to 
multiorgan failure (19). 
ALF etiology is quite diverse; despite similar clinical complications, ALF can be incited by 
viral infection (21), drug-induced injury (22), fungal consumption (23), and bacterial infection 
(24), as well as some genetic disorders such as Wilson’s disease (25). Other causes of ALF can 
be due to heat stroke, pregnancy complications, and ischemia (26). These causes are 
distributed differently across global regions and populations (Figure 1.3) (20). In the United 
States and the United Kingdom, the majority of ALF is caused by acetaminophen (APAP) (also 
known as paracetamol) toxicity. Whereas in eastern and southeast Asia, hepatoviral strains are 
the predominant causes.  
APAP is a non-steroidal anti-inflammatory drug which has been used to treat pain or 
fever for more than half of a century. It is sold without prescription in the United States to 
alleviate symptoms caused by a multitude of diseases. In fact, until the (questionable) decision 
to regularly prescribe opiates for treating pain as vital sign, APAP was the most commonly used 
medication in the United States (27). In the United States, APAP toxicity accounts for 45.7% of 
ALF (Figure 1.4) (28,29). APAP toxicity causes an estimated 78414 emergency room visits 
annually (30). The vast majority (69.8%) of emergency room visits caused by APAP are due to 
self-directed violence (Figure 1.5). However, combination products of opiates and APAP have 
led to an increase in chronic, unintentional, toxicity. These exposures may account for as much 
as 50% of APAP-induced ALF (31). 
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APAP-induced ALF has rapid injury progression, beginning within 8-12 hours following 
ingestion of a toxic dose. APAP toxicity is the principal cause of hyperacute ALF, and has a 
distinct clinical disease pattern (29). APAP toxicity presents with high aminotransferase levels 
(alanine aminotransferase (ALT)) and low bilirubin concentrations, resolving within 3-5 days. In 
APAP toxicity, as much as 65% of patients spontaneously recover without the need for a liver 
transplant (29). 
The mechanism of acetaminophen toxicity has been well described (32,33). 
Consumption of APAP at doses within the therapeutic window process the majority of the drug 
(~85-90%) by sulfation or glucuronidation and excreted as non-toxic metabolites via the 
kidneys. A small portion (~5-9%) undergoes metabolism by the cytochrome P450 enzymes 
CYP2E1, CYP3A4, CYP1A2 (34) to generate the reactive metabolite, N-acetyl-p-benzoquinone 
imine (NAPQI) (35). Typically, NAPQI rapidly reacts with glutathione, an endogenous 
antioxidant synthesized from L-glutamate and cysteine, where it forms conjugants and is 
excreted within the bile. However, when consumed in toxic quantities, these metabolic pathways 
are oversaturated, and excess NAPQI remains free and reactive, where it will bind to other 
proteins to form toxic adducts. These adducts, particularly formed with mitochondrial proteins 
(36), as well as generation of reactive oxygen species, initiate hepatocellular death through 
multiple pathways (Figure 1.6) (37). Interestingly, the distinct pattern of centrilobular necrosis 
observed in APAP toxicity is due to the differences in hepatocellular zonal expression of these 
CYP450 enzymes (Figure 1.7). 
This hepatocyte injury and death produces a sterile inflammatory environment by 
releasing molecules with damage-associated molecular patterns (DAMPs) (38). These are 
endogenous molecules typically reside within the cell membrane, thus avoiding interaction with 
the immune system. The cellular stress caused by APAP toxicity results in release of these 
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DAMPs into the environment where they interact with, and stimulate the immune system (Figure 
1.8) (33).  
As hepatocytes are the predominant source for production for most of the proteins 
involved in the coagulation and fibrinolytic systems, the decreased synthesis due to cell death 
causes disturbances in coagulation. Moreover, the systemic inflammation during ALF 
contributes to alteration of the factors involved in coagulation (Table 1.1) from (39-41). ALF 
patients have an elevated international normalized ratio of the prothrombin time, suggesting an 
enhanced risk of bleeding, yet recent reports suggest less than 10% of patients suffer a bleed, 
which did not correlate with internal normalization times (Figure 1.9) (42). However, survival 
probability in ALF patients was greatest in APAP-induced, non-bleeding individuals (Figure 
1.10) (42). This evidence, along with many other studies completed within the last 15 years (41), 
suggest that the coagulation system enters a “rebalanced” state (39). However, this new 
“balance” might be more sensitive to disruption, and even hypercoagulable (6,39).  
Currently, there is no concrete strategy for thromboprophylaxis. Heparin, and synthetic 
heparin-like molecules have demonstrated to be protective in mouse models typically via their 
mediation of DAMPs (43-45). However, their role in antithrombin affinity for the coagulation 
factors has not been addressed. It’s possible that the efficacy would be impaired as ALF 
patients exhibit low levels of antithrombin (46). Though antithrombin supplementation has been 
attempted in clinical studies (46), no heparin, or heparin analogs were included, and this 
methodology was not shown to confer any benefit. Inhibition of the intrinsic coagulation system 
has not been tested, despite extracorporeal circuit use in the intensive care units (6), and 
increased risk for deep vein thrombosis and pulmonary embolism (47).  
Other unmet needs in ALF has been identification of biomarkers that could stratify 
patients in order to better determine necessity for liver transplantation (48,49). Moreover, while 
APAP -induced ALF has the highest rate of spontaneous survivors, the majority of these non-
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transplanted individuals died within six months (predominantly within the first seven days) of the 
observation phase (48). The majority of those individuals expired due to multiorgan failure, 
suggesting the need for biomarkers that would indicate a patient would transition from ALF to 






























Figure 1.3: Global localization of the etiologies of acute liver failure. Pie charts 
represent percent contribution of cases of liver failure at indicated nations. 
Acetaminophen toxicity accounts for the majority of liver failure cases in the United 































Figure 1.4: Etiological summary of acute liver failure patients in the United 
States. Bar graph from Acute Liver Failures Studies Group findings. Number of 
patients represented on X axis (total n=2611). Y axis indicates the cause of liver 




























Figure 1.5: Acetaminophen exposure leading to emergency room visits. 
Grouped bar graph of percent cases per 100,000 people (X axis) separated by age 
































Figure 1.6: Acetaminophen overdose overwhelms metabolic pathways, leading 
to cell death. CYP = cytochrome P450 enzyme. NAPQI = N-acetyl-p-benzoquinone 



























Figure 1.7: Acetaminophen toxicity has a prototypic pathological presentation 
due to cytochrome P450 localization. A) Hepatic acinus organization. Zone 1 
hepatocytes are closest to portal triads. Zone 2 hepatocytes are between portal 
triads and central veins. Zone 3 hepatocytes are nearest to central vein. B) 
Prototypic pathological presentation of acetaminophen toxicity in liver histology 
Black arrows highlight necrotic areas surrounding central veins. C) 
Immunohistochemical staining of cytochrome P450 3A4. Note that the majority of the 


































Figure 1.8: Acetaminophen -induced hepatocyte death releases damage 
associated molecular patters (DAMPs), leading to immune recruitment. 
Reduced detoxification of NAPQI causes hepatotoxicity, through formation of 
adducts or generation of reactive oxygen species (ROS). These cells release 
DAMPs such as mitochondrial DNA (mtDNA) and high mobility group box 1 
(HMGB1) which signal through Toll-like receptors (TLR) or the receptor for advanced 
glycation endproducts (RAGE), respectively. Cellular signaling causes release of 
cytokines such as monocyte chemotactic protein 1 (MCP-1) tumor necrosis factor α 
(TNFα) and inflammatory interleukins (IL). Cytokin receptor ligation activates 
immune cells, and stimulates nearby hepatocytes for survival via nuclear factor 
kappa-light-chain-enhancer of activated B cells (NFκB) an facilitates immune cell 
recognition via upregulation of intercellular adhesion molecule 1 (ICAM-1). Image 
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Table 1.1: Coagulation abnormalities in acute liver failure. Multiple tissue types 
express bradykinin receptors (BKr). The physiological response to BKr activation 





























Figure 1.9: Elevated internal normalized ratio (INR) in acetaminophen patients 
does not predict bleeding outcome. Acetaminophen -induced acute liver failure 
patients were assayed daily (X axis) for INR (Y axis). Patients with bleeding (open 
triangles) did not have a significantly different INR compared to patients that 































Figure 1.10: Acetaminophen -induced acute liver failure patients who do not 
bleed have greater survival. Kaplan–Meier survival curve depicts probability (Y 
axis) over time (X axis) of acute liver failure patients. Non- acetaminophen (APAP) 
liver failure patients (black lines) compared to APAP patients (grey bars). Note that 
APAP patients with bleeding (grey hashed line) have a significantly lower survival 
probability compared to APAP patients who do not bleed (grey solid line). Image 
published in (42). 
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1.3 High molecular weight kininogen, a critical component of contact activation and more 
High molecular weight kininogen (HK) is a non-enzymatic cofactor for the CS, and 
intrinsic coagulation. It was first discovered when an individual who had suffered a gunshot 
wound had a significantly prolonged clotting time in a laboratory test, but not in the procedure 
room (50). In this assay, plasma FXII is activated by use of a negatively charged surface, such 
as glass, or the silicate mineral kaolin, and time until clotting is measured. The patient was not 
devoid of any of the enzymes in the CS: FXII, FXII, or prekallikrein (PK). Moreover, the clotting 
defect was corrected when the patient plasma was mixed with a normal individual’s plasma. 
This led the physicians to believe there was another clotting factor upstream of FXI, yet it was 
later identified as HK (51), and demonstrated to be a cofactor for FXII activation of FXI and PK 
(52,53). 
HK has several domains, (Figure 1.11) (54) including: domains 3 and 5, which are 
responsible for surface adherence; domain 6, the binding site for FXI or PK; and domain 4, BK 
generation. The vast majority of PK and FXI circulate complexed with HK (55-58), yet HK can 
bind only one molecule at a time (59), and their interaction with FXII is dependent on the 
surface-binding capacity of HK. HK accelerates the FXIIa-mediated activation of FXI to FXIa 
and PK to kallikrein. (PKa) (52). As such, decreased circulating HK concentrations will also 
present as decreased FXI and PK activity (60). Furthermore, PKa can also activate FXII to FXIIa 
in an amplificatory positive feedback loop (61), and this process is enhanced if the enzymes are 
colocalized to a surface (62). Secondary digestion of FXIIa by PKa yields βFXIIa (also known as 
FXIIf) (63). This isoform retains the ability to cleave PK, but possesses less than 5% of the 
activity that FXIIa has for cleavage of FXI; thus, βFXIIa is likely very important in generating PKa 
without downstream coagulation. 
Even before identification of HK as a coagulation cofactor, it was known that bradykinin 
(BK) could be produced from cleavage plasma kininogens (64-66). PKa is the canonical enzyme 
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which cleaves HK to release BK (67). The CS, and BK production is summarized in Figure 1.12. 
BK is a short-lived (68), nonapeptide mediator that is highly vasoactive and inflammatory. There 
are two forms of bradykinin receptors (BKr). BKr2 is constitutively expressed in nearly all 
tissues, whereas BKr1 is synthesized de novo as a response to tissue injury and inflammation 
(69). BK interacts with BKr2 to increase vasodilation, vascular permeability, and inflammatory 
protein kinase cascades (70), as well as other activities summarized in Table 1.2. Septic 
infections, or extensive trauma may result in an elevated concentration of circulating BK. This 

































Figure 1.11: Domain depiction of high molecular weight kininogen (HK). 
Domain 4 (unlabeled) is identified as the bradykinin producing region. Amino 































Figure 1.12: Depiction of the activation of the contact system. FXII binds to an 
anionic surface, facilitating autoproteolytic activation to FXIIa. FXIIa can then 
cleaved FXI to become FXIa, thus initiating intrinsic coagulation. In addition, FXIIa 
can activate prekallikrein (PK), which circulates bound to kininogen (HK), to become 
kallikrein (PKa). PKa can subsequently cleaved FXII to generate more FXIIa as part 
of an amplification step. PKa can also cleave its HK cofactor, and release bradykinin 
























Effect Tissues/Cells Receptors 
vasodilation arterioles BKr2, BKr1 
capillary permeability capillaries BKr2 
venoconstriction veins BKr2, BKr1 
histamine release mast cells BKr2 
prostaglandin release varies BKr2, BKr1 
pain sensory neurons BKr2 
cell migration neutrophils, lymphocytes BKr2 
tissue repair fibroblasts BKr2, BKr1 
broncoconstriction bronchioles BKr2, BKr1 
insulin-like action peripheral tissues BKr2, BKr1 
 
Table 1.2: Biological effects of bradykinin activity. Multiple tissue types express 
bradykinin receptors (BKr). The physiological response to BKr activation (effect) is 




1.4 Measuring activation of the contact system (CS) in plasma 
Investigation of CS activity can be broadly defined as methods that address the potential 
for exogenous activation, and those that focus on analysis of in vivo activation. Tools such as 
clotting assays or substrate cleavage can be used to assess a patient's capacity for CS 
activation using known initiators, as well as discovery of novel putative physiological activators. 
Evidence for in vivo activation is predominantly assayed via enzyme-linked immunosorbent 
assay (ELISA), though Western blot and mass spectrometry have seen specialized use. The 
most common criticisms applied to these assays are the short half-life of the complexes and the 
potential for ex vivo activation during collection. Minimization of pre-analytical activation through 
use of benzamidines or specific CS inhibitors with blood collection (71) is critical and should be 
considered in study design, since FXII may be rapidly activated ex vivo by contact with blood 
drawing equipment (72,73). To our knowledge, there are currently no clinically standardized 




The activated partial thromboplastin time assay (aPTT) uses an anionic surface to 
activate FXII following the addition of phospholipid and calcium. One-stage clotting assays 
based on aPTT using deficient plasma may be used to detect FXI and XII activity. A reduction in 
plasma FXII activity has been regarded as a marker of consumption and, thus, indirect evidence 
of activation of the CS (74). However, given the global nature of the aPTT-based tests, more 





Substrate Cleavage/Chromogenic Assays 
Factors XIIa, XIa and PKa are serine proteases and their enzymatic function can be 
assessed by cleavage of synthetic peptides to generate a chromogenic or fluorogenic signal. 
The most commonly used substrate is S-2302 (H-D-Pro-Phe-Arg-pNA), which is sensitive to 
cleavage by FXIIa and PKa, and to a much lesser extent, FXIa. This substrate mimics the last 
three amino acids in the BK sequence of kininogen, and may therefore be used to address the 
role of FXIIa and PKa in liberation of BK from HK. However, detection of in vivo active enzymes 
using substrates is not practical nor quantifiable. Furthermore, the cross-reactivity of currently 
available substrates is problematic; although several more specific substrates for CS enzymes 
have been developed, the use of specific enzyme inhibitors to minimize the possibility of cross-
reactivity should be considered. For example, corn trypsin inhibitor (CTI) or soybean trypsin 
inhibitor (SBTI) may be added to sodium citrate before blood collection to inhibit FXIIa or PKa, 
respectively (75,76). Similarly, ethylenediaminetetraacetic acid (EDTA) will chelate zinc, (77) a 
required cation in the CS (78), and thus collection of samples in citrate is preferred when 
subsequent assays are intended. 
 
ELISA 
Enzyme-linked immunosorbent assay (ELISA), is a technique which uses specific 
antibodies to capture an analyte from solution, and quantify it by normalizing it to a known 
standard. Depending on the targeted epitopes, these assays may not be able to distinguish 
between zymogen, enzyme or inhibited protein. However, combining this approach with 
evidence of reduced zymogen activity indicates prior CS activation. ELISAs able to distinguish 
activation states offer a greater benefit when analysing clinical samples. Originally developed as 
radioimmunoassays (79), these assays have been modified to ELISA formats that detect CS 
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proteins bound to their physiologic inhibitors including C1 esterase inhibitor (C1), α1-antitrypsin 
(α1at), antithrombin (AT), and α2-antiplasmin. ELISAs for enzyme-inhibitor complexes have 
been used in various disease states (80), yet typically assaying cohort differences, rather than 
establishing a “normal” concentration range. Certain reports concluded that circulating 
complexes do not correlate with disease activity, because of their short half-life (81). However, 
the half-lives of these complexes are estimated in the range of 30 to 50 minutes (82), which can 
still detect chronic CS activation. By analogy, thrombin-antithrombin (TAT) complexes have a 
half-life of ∼15 minutes in plasma, yet are an accepted biomarker of on-going coagulation 
activation in vivo (83). More recently, heavy chain-only nanobodies specific for FXIIa have been 
used to distinguish not only between the activation states of FXII, but also between the α and β 
isoforms (84). Finally, HK can be cleaved by either FXIIa or PKa to release HK fragments. An 
ELISA has been developed to detect cleaved HK in plasma as a marker of contact activation 
(via PKa) due to its longer half-life (∼9 hours) (85,86), but has yet to correlated with BK release, 
or enzyme:serpin assay. 
 
Western Blot 
An alternative approach for detecting activation of the CS activation in plasma is 
Western blotting. Here, detection of enzyme-inhibitor complexes or cleavage of HK (an indirect 
measurement of BK release) provide a semi-quantitative measurement of CS activation (87). 
Western blotting can offer advantages such as the speciation of FXIIa (α or β) when analyzed 
under reducing conditions, or complexes with inhibitors under non-reducing conditions, without 
using specific monoclonal antibodies or the aforementioned nanobodies (88). Detection of 
heavy chain-only HK by Western blotting has shown sensitivity to concentrations as low as 5 
ng/mL (89), with discernible differences in the plasma of rodent models of BK-mediated 
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diseases (90). However, due to the low throughput of Western blotting, clinical samples are not 
typically analyzed using this approach. 
 
Mass Spectrometry 
The major inflammatory effector of the CS is BK, a 9 amino acid peptide generated from 
the cleavage of HK by PKa. Detection of BK versus FXIa (or FXIa-inhibitor complex) provides a 
potentially valuable measurement of the inflammatory versus procoagulant endpoints of CS 
activation. Unfortunately, BK has a circulating half-life < 20 seconds (91) due to its rapid 
metabolism by angiotensin-converting enzyme I (ACE) in the lungs, which greatly limits its 
detection when it is generated in vivo. However, mass spectrometry may be used to quantify the 
major stable metabolite, BK 1–5 (92). Given the evidence for thrombotic protection in mice 
deficient in the BKr2 receptor (92), this underutilized approach should be considered in the 
evaluation of clinical samples. 
 
1.5 Focus of this dissertation 
The role of the contact and intrinsic coagulation systems have never been addressed in 
ALF. Traditional anticoagulants, inhibiting FX or thrombin, have demonstrated some protection 
within the first six hours of the mouse model (93). However, these drugs carry an inherent 
bleeding risk, as sufficient fibrin formation is required for hemostasis. Thus, these therapeutics 
will likely never be considered for use in human disease. Inhibition of the intrinsic coagulation 
cascade has been demonstrated to prevent thrombosis without increasing the bleeding risk 
(94). Therefore, targeting the contact and intrinsic pathways could potentially provide protection 
without the increased bleeding risk. The focus of this dissertation is to 1) develop tools to 
assess contact activation in vivo from human plasma, 2) investigate the effect of deletion of 
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contact and intrinsic pathway proteins, as well as BK inhibition, in the mouse model of ALF, 3) 
evaluate human ALF samples for contact activation and evidence of BK generation, 4) address 
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CHAPTER 2: EVALUATION OF IN VIVO CONTACT ACTIVATION AND HIGH MOLECULAR 
WEIGHT KININOGEN CLEAVAGE 
2.1 Overview 
Mounting evidence suggests that a variety of disease states are pathophysiologically 
related to activation of the CS in vivo. The plasma CS is comprised of a cascade of serine 
proteases initiated by surface activation of FXII, which can then proceed through a procoagulant 
pathway by activating the intrinsic coagulation FXI, or a proinflammatory pathway by activating 
prekallikrein (PK). Serpins are the primary endogenous inhibitors of the CS, which irreversibly 
inhibit their respective protease(s), forming a stable complex. We modified an existing assay 
strategy for detecting these complexes in plasma using ELISAs, and determined the effect of 
preanalytical variation caused by anticoagulant selection and processing time. The assays were 
sensitive and specific to inherited deficiency of individual contact factors. We conclude that 
these assays are robust, and represent a relatively simple approach to the assessment of 
contact factor activation in plasma samples. 
 
2.2 Introduction 
The CS is composed of the zymogens FXII and PK and the cofactor, HK. FXI, of the 
intrinsic coagulation pathway, is often considered a component of this pathway, as it is activated 
by the enzymatically active form of FXII (FXIIa). Thereafter, activation of FIX by FXIa proceeds 
to the common coagulation pathway resulting in thrombin generation. Activation of the CS is by 
direct contact of FXII with negatively charged surfaces, an interaction that results in a 
conformational change to reveal the active site of FXII. FXIIa can then cleave and activate FXI 
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and/or PK, resulting in the generation of the active enzymes, FXIa or kallikrein (PKa), 
respectively. Additionally, activation of FXII and PK generates a reciprocal feedback loop, which 
may overcome the inhibitory capacity of the checkpoint serine protease inhibitors (1). The 
dominant inhibitor of FXIIa and PKa in plasma is C1 (2). Although FXIa is also principally 
inhibited by C1, it may also be inhibited by alpha-1 antitrypsin (α1at), apha 2 antiplasmin, and 
(particularly in the presence of heparin) antithrombin (AT) (3). Finally, activated FIX (FIXa) is 
mainly inhibited by AT in plasma, the efficacy of which is logarithmically increased by the 
addition of heparin (4).  
A recent resurgence of interest in the role of the CS in thrombosis and inflammatory 
disorders (5-7) has not been accompanied by a widespread adoption of assays to assess acute 
or chronic activation of the CS in clinical settings. We therefore re-evaluated and adapted an 
existing methodologic approach to measure in vivo CS activation using an enzyme-linked 
immunosorbent assay (ELISA) platform (8). The panel of assays we describe allow 
quantification of complexes of the CS enzymes with their serpins in human plasma. We herein 
describe assays that allow detection of the following complexes: FXIIa:C1, PKa:C1, FXIa:C1, 
FXIa:α1at, FXIa:AT, and FIXa:AT. A major challenge in measuring CS complexes is the 
potential for artifactual ex vivo contact activation after blood is drawn into collection vials. Thus, 
in order to determine the ideal conditions for assaying activity of CS complexes, we also sought 




All reagents are commercially available. Monoclonal antibodies against FIXa and FXIa 
were purchased from Haematologic Technologies (Essex Junction, VT USA). Anti-PKa was 
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purchased from Molecular Innovations (Novi, MI USA) and anti-FXIIa was acquired from 
Molecular Innovations (Novi, MI USA). A polyclonal antibody against AT was purchased from 
Haematologic Technologies (Essex Junction, VT USA), and anti-α1at was purchased from 
Abcam (Eugene, OR USA). Polyclonal anti-C1 was purchased from Agrisera (Vännäs, 
Sweden), and monoclonal was purchased from R&D Systems Minneapolis, MN USA). All 
detection antibodies were biotinylated using EZ-Link Sulfo-NHS-Biotin (Thermo, Waltham, MA 
USA). Assay plates were Nunc Maxisorp (Thermo, Waltham, MA USA). Blood collection tubes 
containing sodium citrate (105–109 mmol/L), sodium heparin, and ethylenediaminetetraacetic 
acid (EDTA) were purchased from Becton Dickinson (Franklin Lakes, NJ USA). SCAT-27 tubes 
containing citrate and corn trypsin inhibitor (CTI) were purchased from Haematologic 
Technologies (Essex Junction, VT USA). Factor-deficient plasmas for factors IX, XI, and XII 
were purchased from George King Bio-Medical (Overland Park, KS USA), and PK-deficient 
plasma was purchased from Diapharma (West Chester, OH USA). Kaolin was purchased from 
Sigma Aldrich (St. Louis, MO USA).  
 
Sample Collection and Processing 
Seven (3M, 4F) healthy control individuals (mean age 34.6 ± 9.3 years) were recruited. 
No subject had a history of thrombosis, bleeding or angioedema, and none had never received 
a blood product. No individual was currently taking any antiplatelet or anticoagulant therapies. 
All patients were fasted for at least 10 hours prior to collection. The same phlebotomist 
conducted all of the blood draws to limit variability in sampling technique. All samples were 
collected under an approved Institutional Review Board protocol for venipuncture. Blood 
samples were obtained by antecubital venipuncture using a 21G butterfly needle. The first 3mL 
of blood was discarded. Blood was drawn into vacuum tubes containing anticoagulant, mixed by 
5 end-to-end inversions, and plasma was prepared by two successive centrifugations at 2500 x 
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g for 15 minutes at 21°C. All plasmas were frozen within 40 minutes of initial blood draw, 
including centrifugation time, aside from studies evaluating the effect of time until processing.  
Enzyme:Serpin Complex ELISA Assays 
Assay standards were generated by incubating the active enzyme with its respective 
inhibitors at a 1:8 molar ratio for 5 hours at 37°C, with gentle mixing every 1 hour, in phosphate 
buffered saline (PBS). When using AT, 1 U/mL heparin was added to the mixture. Enzyme-
inhibitor complex standards were diluted to 1μM enzyme concentration and aliquoted for 
storage at  80°C. It was assumed that the molar concentration of the complexes is equivalent to 
the concentration of the coagulation enzyme in the standard preparation. Each standard was 
tested for enzymatic activity using the following chromogenic substrates: FXIIa -S2302 
(Diapharma); FXIa - S-2366 (Diapharma); PKa - PKAL (American Diagnostics); FIXa - 
Pefachrome IXa (Pentapharm). Standards were diluted into deficient plasma for the respective 
factor of interest, obtained from individuals with severe genetic deficiency and certified to have < 
1% factor activity; e.g. FXIIa:C1 complexes were serially diluted into FXII-deficient plasma. 
Deficient plasmas were used as blank calibration controls.  
 Capture plates (either 96 or 384 well formats) were coated (100µl) with either 1μg/mL (FIX 
or FXI) or 2μg/mL (FXII or PK) capture antibody overnight (15 hours) at 4°C, in a commercially 
available coating buffer (eBioscience). Wells were washed 3 times with PBS containing 0.01% 
Tween 20, inverting and blotting after each wash to absorb excess buffer. Wells were then 
blocked with 1% BSA at room temperature for 1 hour. The wash steps were repeated prior to 
sample loading. Plasmas for assay of FIXa:AT, FXIa:AT, or FXIa:α1at were diluted 1:20, while 
for FXIa:C1 and FXIIa:C1, samples were diluted 1:40, and for PKa:C1, 1:160, unless otherwise 
noted. These samples were diluted into PBS containing 5mM benzamidine and 25µM Phe-Pro-
Arg-chloromethylketone (FPRck) to inhibit further enzymatic activity. After a 2-hour sample 
incubation at room temperature plates were again washed x3 as before. Biotinylated anti-C1 
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antibody was then added at 50ng/mL in PBS, while anti-AT or anti-α1at were added at a final 
concentration of 90ng/mL. All were incubated for 1 hour at room temperature. Following another 
series of washes, SAV-HRP was added according to the manufacturer’s specifications. After a 
final series of washes, TMB substrate was added, and quenched with 0.18M sulfuric acid after a 
development period of 10 minutes at room temperature, making sure to shield the plate from 
light. The colorimetric readout was assessed using a spectrophotometer measuring absorbance 
at 450nm wavelength.  
 
Substrate cleavage assay 
Factor XII zymogen (370nM) was added to buffer containing 100µM S-2302 substrate, 
and varying concentrations of dipotassium EDTA. Substrate cleavage was indicated by optical 
density at 405nm using a Bio-Tek Synergy H1 plate reader (Winooski, VT, USA). 
 
FXIa Un-activated Clotting Time 
FXI-deficient plasma was supplemented with 30nM of synthetic phospholipid, and mixed 
with HEPES buffered saline ± FXIa and 12.5mM calcium. Immediately, using a Stago Start 
analyzer, the protocol for activated partial thromboplastin time (aPTT) was initiated. Clotting 
time was assessed when mechanical translocation of a bead was inhibited by coagulation and 







Statistical Analysis  
Statistical analysis was conducted using Graphpad Prism V8 (La Jolla, CA). Comparison 
of two groups was performed using Student's t-test. Comparison of three or more groups was 
performed using one- or two-way analysis of variance, as appropriate, and the Student-
Newman-Keuls post hoc test. Data are displayed as mean ± standard error of the mean. p 
<0.05 confers statistical significance. 
 
2.4 Results 
Assay Design and Validation of Standards 
The basic design of enzyme:inhibitor complex  ELISA, which captures the enzymatic (E) 
component and probes for complexes using antibodies against the respective inhibitor (I) is 
shown in Figure 2.1. Zymogen-deficient plasma was used as the diluent for the respective 
enzyme:serpin standard. Figure 2.2 depicts the standard curves generated by adding 
complexes into these deficient plasmas, compared to complexes in buffer alone. Additionally, 
use of monoclonal versus polyclonal antibody for detection was compared (Supplemental Figure 
2.1). These data demonstrate that enzyme capture, and assay range is accurate in both plasma 
and buffer. Moreover, usage of either a polyclonal, or monoclonal antibody in serpin detection 
maintains the assay range. 
We utilized substrate cleavage assays to verify that the standards contained minimal 
residual enzymatic activity. Enzyme-serpin complexes were incubated with an appropriate 
chromogenic substrate for 45 minutes at 37°C and change in optical density over time was 
recorded (Figure 2.3). Enzyme alone was used as a positive control. In all assays, activity of the 




Assay Development and Analytical Performance 
ELISAs were tested for specificity and cross-reactivity by assaying 200nM of each pre-
formed complex in each assay. Percent cross reactivity was calculated by dividing the 
calculated concentration of a cross-reactive complex by the calculated concentration of the 
antigen with its intended antibody pair. These data are summarized in Table 2.1. For enzymes 
inhibited by AT or α1at, there was <1% cross reactivity in all assays. For enzymes inhibited by 
C1 there was slightly more cross reactivity, with the highest level of cross reactivity seen in 
complexes of FXIIa:C1 that cross reacted at a level 3.2% in the assay intended for PKa:C1. 
These data indicate that all assays have acceptably low cross reactivity at >10-fold saturating 
concentrations of the analytes.  
Next, the assays were tested for intra- and inter-assay variability. Four control samples 
were generated by the addition of 2, 20, 200 µg/mL kaolin or vehicle plus 1U/mL heparin, 
12.5mM calcium chloride, and 4U/mL hirudin to normal plasma, followed by a 1-hour incubation 
at 37°C. After activation was quenched using benzamidine and FPRck, kaolin particulate was 
centrufiged to pellet, and the plasma supernatant was frozen at -80°C. These samples were run 
in octuplicate on each plate. Intra-assay variability was calculated by averaging the deviation of 
each test well from the mean value of all test wells for the same control sample in a single plate. 
Inter-assay variation was calculated by determining the deviations of those averages across 15 
plates. Table 2.2 summarizes the average variation of 15 plates of each assay depicted. 
Overall, the reproducibility was good, with the coefficient of variance consistent with a typical 
clinical assay. 
Verification of the specificity of the assays was performed by contact activation of factor-
deficient plasmas by kaolin. Following activation, samples were spun to pellet the kaolin 
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particulate, and supernatants were collected and frozen overnight. Plasma enzyme:serpin 
complexes were then quantified, as summarized in Table 2.3. We did not observe a significant 
increase in detected enzyme:serpin complexes in any factor-deficient plasma following CS 
activation. However, activation of normal pool plasma (NPP) significantly increased the 
concentration of enzyme:serpin complexes in all cases. Collectively, these data suggest that 
capture of enzyme, and probing for serpin, is an effective methodology to assay activation of the 




To determine if the anticoagulant used in the blood collection tubes contributed to 
variation in results, blood was collected into 5 different types of vacuum tubes at a single draw. 
Plasma was prepared from these tubes within 40 min of blood collection and stored at -80°C. 
These samples were then subjected to assay of the various enzyme:serpin complexes. Fold 
change from citrate for tubes containing EDTA, FPRck (in citrate), heparin, and CTI (in citrate) 
was calculated. In all assays, plasma in tubes containing EDTA differed significantly from citrate 
alone (Figure 2.4). Specifically, EDTA caused a significant increase in the concentration of 
detected complexes, possibly due to exogenous activation. In the assay detecting FXIIa:C1 
complexes, CTI + citrate significantly reduced the concentration of detected complexes 
compared to citrate alone. However, in no other assay did the addition of CTI affect complex 
quantitation. In no assay did the addition of FPRck to citrate, or collection in sodium heparin 
have a significant effect on detected complex levels.  
To identify the mechanism of increased complex detection in EDTA anticoagulant 
collection tubes, we designed studies to address if this was dependent on the cellular fraction. 
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In the first experiment, whole blood collected in EDTA or citrate was mixed in a 1:1 ratio prior to 
separation of plasma. Separately, citrated plasma was added to a fresh vacutainer tube 
containing EDTA prior to a second centrifugation. These samples, labeled “blood 50/50” and 
“plasma 50/50”, respectively, were assayed for enzyme:serpin complexes (Figure 2.5). 
Interestingly, the presence of EDTA in the “blood 50/50”, or in “plasma 50/50” increased 
detection of FXIa:α1at and PKa:C1 complexes to levels comparable to direct collection of whole 
blood into EDTA. Previous work in our laboratory has suggested that commercially available 
preparations of FXII zymogen may be contaminated by small amounts of FXIIa, or may undergo 
auto-activation even if stored at -80°C. Thus, EDTA may not be directly responsible for new 
FXIIa generation, but rather may increase the activity of any existing FXIIa. Using two different 
commercial preparations of FXII, we tested the enzymatic activity using a FXIIa-specific 
substrate in different concentrations of EDTA (Supplemental Figure 2.3). In both preparations, 
baseline substrate cleavage was enhanced by increasing EDTA concentration, suggesting that 
if FXII is activated during blood collection, EDTA may increase that rate of activation, or its 
activity, leading to complex formation. 
 
B] Processing Time 
The effect of elapsed time following collection on ex vivo activation of the CS was 
evaluated using the respective ELISA. Collection tubes were placed upright at room 
temperature for 0, 1, 2, or 8 hours prior to centrifugation, or agitated for 1 hour. In no case were 
we able to detect any significant difference in complex quantitation after 1 hour of incubation, 
even when agitated (Figure 2.6). However, following 2 hours of incubation, FXIIa:C1 levels 
increased significantly. At 8 hours post blood draw, FXIIa:C1, FXIa:C1, and FXIa:α1at 
demonstrated a significant increase in complex formation, likely indicative of time-dependent ex 





In this communication, we describe the analytic and pre-analytic characteristics of 
several ELISA assays that can be used to measure the in vivo generation of enzymes of the 
contact and intrinsic pathways. The data presented herein suggest that these assays provide a 
sensitive, specific, and reproducible methodologic approach. The choice of anticoagulant 
demonstrated significant differences within the same patient sample, with EDTA apparently 
causing increased ex vivo formation of all complexes assayed. EDTA anticoagulation has been 
demonstrated to produce higher D-dimer levels compared to citrate (9), supporting this 
rationale. It is possible that anticoagulant selection may influence sample pH, though reports 
differ (10, 11). However, decreasing pH has been demonstrated to reduce FXII-surface 
interaction (12). The addition of CTI was necessary to prevent ex vivo FXIIa:C1 complex 
formation, an indicator of ex vivo surface activation of coagulation in the collection tubes. (13).  
 
Measurement of enzyme:serpin complexes in plasma is an established approach to 
assess activation of coagulation pathways; for example, quantitation of thrombin:antithrombin 
(TAT) and plasmin:antiplasmin (PAP) complexes are accepted biomarkers of coagulation and 
fibrinolysis activation, respectively. The assays that we have developed are modified versions of 
previously described ELISAs that have been used to measure in-vivo contact activation in 
sepsis (2, 14, 15), endotoxemia (16), dengue fever (17), and cardiovascular disease (18, 19). 
Importantly however, in those studies, quantitation of FXIIa:C1 and PKa:C1 complexes was 
performed by capturing C1 using a monoclonal antibody that detects a neoantigen present in 
cleaved or FXIIa- or PKa-bound C1 (2). The currently described approach offers several 
advantages, specifically: a] quantitation of total antigen (zymogen and complexes) within the 
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same dilution allows generation of a ratio of activation without extrapolation across separate 
assays; b] samples can be probed for multiple discrete serpins while keeping enzyme 
concentration constant to determine inhibition ratios; and c] given that the zymogens circulate at 
a much lower concentration than the serpins, a much greater sensitivity and a larger analytical 
fraction can be achieved. For enzymes that are inactivated by several proteases, the plasma 
concentrations of the various serpin-bound complexes will depend on their circulating half-life 
(t1/2). Thus, for example, while C1 is the dominant inhibitor of FXIa in plasma (accounting for 
almost 50% of FXIa inactivation), its relatively shorter plasma t1/2 of approximately 100 minutes 
means that in the presence of acute activation of coagulation, the measured levels of FXIa:α1at 
– which accounts for only about 25% of FXIa inactivation but has a circulating t1/2 of 
approximately 350 minutes – will be relatively ‘over-represented’ (20). Moreover, it has been 
demonstrated that addition of heparin to the sample results in a shift in the percentage of FXIa 
bound to AT (3). This serves as an important consideration when analyzing plasmas from 
individuals with central venous access, or heparinized intravenous needles, such as dialysis 
patients or the critically ill. Inferring circulating enzymatic levels of a factor with multiple potential 
serpins, such as FXIa, from summation of the levels of these complexes is one strategy that 
could be used. Addition of a known concentration of FXIa directly to FXI-deficient plasma and 
using these assays to “recover” the enzyme could be calculated as input versus output, 
providing a measure of total enzyme activity (3). An alternative strategy would be to couple the 
analysis of complexes with total zymogen/enzyme levels, and to ascertain the percentage of 
circulating activated zymogen, perhaps in a dual-color fluorescent immunoassay. Low amounts 
of FXIa can lead to thrombin generation (21), suggesting a need for highly sensitive assays that 
can detect activation in non-severe disease states. The assays for FXIa used in this report for 
FXIa are sensitive between concentrations as low as 10-40pM, similar to earlier reports (3). We 
measured plasma clotting time following titration of FXIa (Supplemental Figure 2), and found 
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that this our assays could sufficiently detect FXIa activity at levels which would affect a normal 
clotting assay. 
Several alternative approaches to assess contact system activation in vivo have been 
proposed. Deficiency of individual zymogens and/or HK by one-stage clotting assay has been 
used to infer ongoing factor consumption in some studies (22). Similarly, ELISA assays that 
quantify deficiency of these zymogens, which is presumed to be acquired, have been similarly 
interpreted (22, 23) Other groups have used functional assays to measure circulating active 
enzyme concentrations by the use of chromogenic or fluorogenic substrates (24), or by clotting 
activity-based assays (25). In addition, a number of specific isoform antibodies or nanobodies 
have been developed to quantify free (uncomplexed) activated FXII species (26, 27). Finally, 
several groups have developed assays to quantify HK cleavage products, including bradykinin 
(28, 29). To our knowledge, no studies have directly compared the performance or utility of 
these assays as diagnostic or prognostic clinical aids, although the range of applications is 
potentially very broad. One such application is inherited deficiency of C1 esterase inhibitor, 
which is associated with hereditary angioedema, a disorder characterized by episodic and 
sometimes life-threatening soft tissue swelling. Similarly, these assays may find utility in the 
assessment of contact and/or intrinsic pathway activation in thrombotic disorders where animal 
models suggest that inhibition of FXI(a) or FXII(a) may provide safe and effective 
anticoagulation (5-7). Lastly, as we have shown, the assays may be used to establish the 
diagnosis of inherited deficiency of any of the contact or intrinsic factors following activation of 
































Figure 2.1: Illustrated concept of enzyme:serpin complex ELISA. Monoclonal 
antibodies (blue) specific to the enzymes (E) of the CS are used to coat the surface 
of an assay plate. Enzymes that have been inhibited (I) by a serpin are detected by 


































Figure 2.2: Assay sensitivity range. Plots of enzyme:serpin complex standards 
diluted into factor-deficient plasmas (gold), versus buffer (black). A-F: Concentration 






























Figure 2.3: Generation of assay standards. Equal nM concentration of active 
enzyme (dashed lines), or enzyme:serpin complexes (solid lines) generated in vitro, 
were mixed with chromogenic substrates specific for the respective enzyme. Change 
in absorption of 450nm light measured by optical density (OD) is indicated on the Y 
axis, and time in minutes is indicated on the X axis. A: FIXa and FIXa:AT 
complexes. B: FXIa and complexes of FXIa:α1at, FXIa:AT, and FXIa:C1. C: FXIIa 
versus XIIa:C1 complexes. D: PKa compared to PKa:C1 complexes. Data are 
representative of two independent experiments; each condition was measured in 


















































FIXa:AT   0.4 0.0 0.2 0.2 0.3   
FXIa:AT 0.9   0.0 0.5 0.2 0.1   
FXIa:α1at 0.0 0.0   0.4 0.0 0.2   
FXIa:C1 0.0 0.1 0.3   1.8 1.8   
FXIIa:C1 0.0 0.0 0.0 0.9   1.7   
PKa:C1 0.0 0.0 0.0 2.2 3.2     
Capture               
 
Table 2.1: Cross reactivity of assay standards. Rows represent the intended 
capture and detection strategy, while columns represent the complex standard used. 
Intersecting boxes represent the percent cross-reactivity. Data depict the average 






















  cv intra-assay cv inter-assay 
FIXa:AT 5.9 ± 0.5 11.9 ± 1.1 
FXIa:AT 4.1 ± 0.3 10.5 ± 1.8 
FXIa:α1at 6.5 ± 0.9 13.2 ± 2.5 
FXIa:C1 6.8 ± 0.6 17.1 ± 1.9 
FXIIa:C1 4.8 ± 0.4 7.9 ± 0.7 
PKa:C1 5.1 ± 0.8 7.5 ± 0.4 
 
Table 2.2: Coefficient of variance (CV) within each assay, and across multiple 
assays. Rows specify the assay performed, and columns represent intra- and inter-
assay CV values as defined. Intra-assay variation was calculated as an average 
variation of four different control samples assayed in octuplicate per plate. Inter-assay 















  FIXa:AT FXIa:AT FXIa:α1at FXIa:C1 FXIIa:C1 PKa:C1 
NPP 0.71 ± 0.02 0.22 ± <0.00 0.3 ± 0.04 0.14 ± 0.02 9.01 ± 0.24 8.96 ± 0.03 
NPP + 
Kaolin 44.64 ± 2.06 5.99 ± 0.43 4.55 ± 0.09 7.3 ± 0.16 56.36 ± 1.19 
236.25 ± 
10.88 
Deficient 0.84 ± <0.00 0.19 ± <0.00 0.19 ± 0.01 0.13 ± <0.00 1.81 ± 0.44 8.22 ± 0.11 
Def + 
Kaolin 0.82 ± 0.02 0.19 ± <0.00 0.18 ± <0.00 0.13 ± <0.00 2.17 ± 0.15 8.48 ± <0.00 
 
Table 2.3: Activation of factor-deficient plasmas. Rows indicate the type of plasma and 
activation status. NPP= normal pooled plasma, Kaolin = 50μg/mL kaolin at 37°C for 1 hour. 
Deficient (def) plasmas correspond to the complex being assayed; for example, FIX-deficient 
patient was assayed for FIXa:AT complexes. Columns represent the assay being performed. 
Intersecting boxes indicate the nM concentration of complexes detected in the samples. These 

































Figure 2.4: Tube selection as a preanalytical variable in contact activation 
analysis. Seven normal individuals were assayed following collection of blood into 
vials pre-filled with various anticoagulant(s) as depicted on the X axis: citrate =3.2%, 
EDTA = 7.2mg; FPRck = 25μM, sodium heparin =75 units; CTI = 50µg/mL. The Y 
axis shows the -fold change in complexes detected (μM) relative to concentration in 

































Figure 2.5: Effects of EDTA on contact activation in whole blood versus plasma. 
Enzyme:serpin analysis on plasmas collected in various anticoagulants as indicated. 
All values shown are relative to pM complex concentration detected in citrated plasma. 

































Figure 2.6: Delayed processing time contributes to ex vivo activation of the CS. 
Blood was collected from seven normal individuals and allowed to incubate at room 
temperature for given time points, or agitated (Agit) for one hour. The X axis 
represents the time course in hours. The fold change from citrate at 0 hours was 
calculated per patient, illustrated on the Y axis. * = P≤0.05, ** = P≤0.01. 
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Supplemental Figure 2.1: Comparison of monoclonal versus polyclonal 
detection antibodies. A-C: Concentration of complex standard (X axis) and 
respective absorbance (Y axis) when using monoclonal (blue) versus polyclonal 





























Supplemental Figure 2.2: FXIa concentration and clotting times. Dashed bar 
represents the limit of detection (600 sec). The X axis represents the pM 
concentration of added FXIa. The Y axis represents the mount of time in seconds, 
until clot was formed. 0= vehicle (buffer, calcium, and plasma alone). K20= 20µg/mL 
































Supplemental Figure 2.3: EDTA increases enzymatic activity of FXII(a) in 
buffer. Factor XII zymogen from two different vendors, A) Enzyme Research Labs 
[ERL], B) Hemetech, was added to buffer containing substrate, and indicated 
concentrations of dipotassium EDTA (mM). Substrate cleavage was indicated by 
optical density at 405nm (Y axis) over time (X axis). Negative control (buffer) was 
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CHAPTER 3: KININOGEN DEFICIENCY IS PROTECTIVE IN A MOUSE MODEL OF 
ACETAMINOPHEN TOXICITY 
3.1 Overview 
APAP-induced liver injury is associated with activation of coagulation and fibrinolysis. In 
mice, both tissue factor-dependent thrombin generation and plasmin activity have been shown 
to promote liver injury after APAP overdose. However, the contribution of the contact and 
intrinsic coagulation pathways has not been investigated in this model. Mice deficient in 
individual factors of the contact or intrinsic coagulation pathway were administered a 
hepatotoxic dose of 400 mg/kg of APAP. Neither FXII, FXI, nor PK deficiency mitigated 
coagulation activation or hepatocellular injury. Interestingly, despite the lack of significant 
changes to APAP-induced coagulation activity, markers of liver injury and inflammation were 
significantly reduced in APAP-challenged high molecular weight kininogen-deficient (HK-/-) 
mice. Protective effects of HK deficiency were not reproduced by inhibition of bradykinin-
mediated signaling whereas a reconstitution of circulating levels of HK in HK-/- mice reversed 
them. Fibrinolysis activation was observed in mice after APAP administration. Western blotting, 
ELISA, and mass spectrometry analysis demonstrated that plasmin efficiently cleaves HK into 
predicted fragments in buffer or plasma. Importantly, plasminogen deficiency attenuated APAP-
induced liver injury and prevented HK cleavage in the injured liver. Finally, enhanced plasmin 
generation and HK cleavage, in the absence of CS activation were observed in plasma of 
patients with acute liver failure due to APAP overdose. In summary, extrinsic, but not intrinsic 
coagulation drives coagulation-mediated pathologies associated with APAP-induced liver injury 
in mice. Furthermore, plasmin, rather than FXIIa-dependent generation of kallikrein, contributes 
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to HK cleavage and hepatotoxicity in APAP-challenged mice independently of thrombin 
generation and bradykinin signaling. 
 
3.2 Introduction 
APAP (Paracetamol™; Tylenol™) overdose is the leading cause of drug-induced acute 
liver failure (1), and is responsible for more than 78,000 emergency room visits annually in the 
United States (2). Hepatocellular injury is initiated when excess APAP is metabolized by 
cytochrome P450 enzymes into the reactive intermediate N-acetyl-p-benzoquinone imine 
(NAPQI) (3-6), which generates protein adducts (7), leading to oxidative stress and 
mitochondrial dysfunction (8,9). Permeabilization of the mitochondrial membrane and cessation 
of ATP synthesis ultimately results in hepatocyte death that can progress to acute liver failure 
(ALF) (10).  
Several reports in mouse models indicate that anticoagulation mitigates the early phase 
of APAP-induced hepatotoxicity (11-13), but paradoxically, coagulation factors participate in 
liver regeneration during the recovery phase (14). Specifically, genetic reduction of tissue factor 
expression or pharmacologic inhibition of thrombin activity result in significant reduction of liver 
injury early after APAP ingestion (11,13). The pathologic contribution of thrombin during the 
early stages of APAP-induced ALF is in part mediated by activation of protease activated 
receptors (PARs) (13) and also requires fibrin(ogen) (11,12). However, during the repair phase 
following APAP overdose, fibrin(ogen) is required for leukocyte-mediated liver repair (14).  
Fibrinolysis is principally initiated by tissue plasminogen activator (tPA)-mediated 
cleavage of plasminogen to generate plasmin (15). Recently, it was reported that animals 
deficient in plasminogen are less susceptible to APAP-induced liver toxicity (12), and 
mechanisms are currently being investigated (16). Interestingly, it has been shown that 
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plasminogen activators may contribute to the APAP-induced liver injury independently of 
fibrin(ogen) (12). In addition to being the main effector enzyme of the fibrinolytic system, 
plasmin has been also shown to have other functions, including cleavage of high molecular 
weight kininogen (HK) (17-19). However, data demonstrating the in vivo relevance are missing.  
Activation of FXII leads to two events: (i) propagation of coagulation by activation of FXI 
and (ii) activation of plasma prekallikrein (PK), with subsequent kallikrein (PKa)-mediated 
cleavage of HK resulting in the release of bradykinin (BK) and cleaved HK fragments (20). In 
addition, HK is also a co-factor for FXIIa-dependent activation of FXI and PK. There is growing 
interest in therapeutic targeting of enzymes of the intrinsic pathway (FXIIa or FXIa) to prevent 
thrombosis, primarily because this goal may be attainable without incurring a significant 
bleeding risk (21-25). However, the role of this pathway or CS in ALF has not been investigated. 
In this study, we investigated whether the FXIIa-mediated activation of CS and intrinsic 
coagulation pathway contribute to the pathology observed in a mouse model of APAP-induced 
liver injury. We hypothesized that deficiency of FXII and/or FXI would attenuate thrombin 
generation and provide protection against hepatic injury. Furthermore, we postulated that FXII 





Study patients who participated in the Acute Liver Failure Study Group Registry have 
been described (26). All study patients met criteria for ALF as defined previously (27). The 
etiology of ALF as APAP overdose was initially identified by the study site investigator, and 
adjudicated by the ALF Study Group Causality Committee (28). Plasma samples were collected 
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in citrated Vacutainers (4 ml) on admission, processed, and stored at the NIH/NIDDK 
Repository at -80°C until used in the current studies. Consent was provided by the patients’ 
legal next-of-kin. Institutional Review Boards of each participating institution approved the ALF 
Study Group Registry and Biorepository. 
Mice 
All studies were performed in male mice, 10 to 14 weeks of age. Wild-type C57Bl/6J 
mice were purchased from the Jackson Laboratory (Bar Harbor, ME). FXII-/- animals have been 
previously described (29). FXI-/- mice were kindly provided by Dr. David Gailani (30). PK-
deficient mice were developed at the Texas Genomic Institute, and obtained from Dr. Alvin 
Schmaier (31). Generation of HK-/- and plasminogen-deficient mice was described previously 
(32 33). All experimental mice were on the same genetic background. All animals were 
maintained at the University North Carolina in a facility accredited by the Association for 
Assessment and Accreditation of Laboratory Animal Care International, according to the criteria 
of the Guide for the Care and Use of Laboratory Animals (34). Mice were housed at an ambient 
temperature of 22°C with 14/10-hour light/dark cycles and were provided water and rodent chow 
ad libitum. All animal procedures were approved by the Institutional Animal Care and Use 
Committee of the University of North Carolina.  
 
APAP Model  
Mice fasted for approximately 14-16 hours were given a sublethal dose of 400 mg/kg 
APAP (35) (Sigma Aldrich, St. Louis, MO) or vehicle (sterile saline solution) by intraperitoneal 
injection, and food was returned ad libitum. At indicated times after APAP administration, mice 
were anesthetized using isoflurane (Eagle Eye Anesthesia, Jacksonville, FL). Blood was 
collected from the caudal vena cava into sodium citrate (3.8%) and centrifuged at 2,000 x g for 
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20 minutes to isolate platelet poor plasma. The liver was removed and washed with sterile 
saline. The left lobe was removed and fixed in 10% neutral-buffered formalin for 24-36 hours.  
 
Clinical Chemistry 
Serum ALT was determined using a commercially available reagent (Infinity ALT, 
Thermo Fisher, Waltham, MA). Data were acquired using a Synergy H1 plate reader (BioTek, 
Winooski, VT).  
 
Plasma ELISA Assays 
Mouse IL-6 was analyzed using a commercial kit from R&D Systems (Minneapolis, MN). 
Active tPA was quantified using a kit from Molecular Innovations (Novi, MI). Mouse plasmin-α2 
antiplasmin (PAP) complexes were detected using a kit from CusaBio (College Park, MD). 
Human PAP complexes were detected using an assay obtained from Diapharma (West 
Chester, OH). Plasma thrombin-antithrombin III levels (TAT) were determined using a 
commercial enzyme-linked immunosorbent assay kit (Siemens Healthcare Diagnostics, 
Deerfield, IL). All assays were performed according to the manufacturer’s specifications with no 
modification. Bradykinin assay was obtained from Enzo Life Sciences, and conducted according 
to the manufacturers protocol (Farmingdale, NY). Assays detecting total HK levels, cleaved HK 
levels have been recently described (36). Assays detecting complexes of FXIIa, FXIa, PKa, with 






Clot Lysis Time 
The detailed methodology of the tPA resistance assay was recently described (38). In 
brief, coagulation and fibrinolysis are simultaneously initiated by the addition of tissue factor, 
Ca2+ and tPA to platelet-free plasma. The optical density changes are recorded over 24 hours, 
at which point the test is terminated. The time from 50% maximal clotting to 50% lysis is defined 
as the clot lysis time (CLT).  
 
Histopathology & Hematology 
Formalin-fixed livers were sectioned at 4 μm intervals, stained with hematoxylin and 
eosin (H&E), and evaluated under light microscopy. Three sections of liver from the left lobe 
were evaluated from each animal. The area of hepatocellular necrosis from the central vein was 
quantified by perimeter measurements in several low magnification (×40) images using Image J 
software (Wayne Richards, NIH, Bethesda, MD), as previously shown (39). Histological scoring 
criteria (Supplemental Table 1) were evaluated by Dr. Stephanie Montgomery, Director, UNC 
Animal Histopathology Core. Scoring was conducted by two independent lab personnel, who 
were blinded to treatment groups. Complete blood counts were quantified using a Heska HT5 
veterinary analyzer (Loveland, CO). 
 
Immunohistochemistry 
Paraffin sections from livers of APAP-treated mice were subjected to antigen retrieval 
(10mM citrate buffer, pH 6.0) for 25 minutes at 95°C. Endogenous peroxidase and endogenous 
biotin were blocked using hydrogen peroxide and avidin/biotin blocking kit (Vector Laboratories), 
respectively. Neutrophil staining was performed using a rat anti–mouse neutrophil monoclonal 
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antibody (1:1000, NIMP-R14; Abcam). Subsequently, sections were incubated with a 
biotinylated anti–rat secondary antibody (Vector Laboratories), followed by Vectastain ABC kit 
reagents (Vector Laboratories). Slides were developed using ImmPACT DAB peroxidase 
substrate (Vector Laboratories) and counterstained with hematoxylin (Dako). Images were 
captured with the D80 digital camera (Olympus America) attached to the Olympus DX51WI 
microscope at final magnifications of 40x. Quantitation of staining was performed using Fiji 
(Image J). Briefly, images were white-balanced by background subtraction. Images were color 
de-convoluted according to H DAB software defaults, and the color (40) image was converted 
using the ‘Grays’ look up table, then converted to 8-bit black and white. This binary image was 
measured using the particle analysis protocol. 
 
Western Blot 
Liver tissue (25 mg) was homogenized in RIPA buffer in the presence of protease 
inhibitors (Roche, Boston, MA). A total of 36 µg liver protein was loaded per well into a TGX 
10% gel, and subsequently transferred to 0.2 µm nitrocellulose membrane (Bio-Rad, Des 
Plaines, IL). Membranes were blocked in tris-buffered saline with 5% non-fat dry milk overnight 
at 4°C. A rabbit polyclonal antibody raised against HK was used to detect the full-length and 
cleaved forms (2). Anti-rabbit Alexa 790 (Thermo Fisher, Waltham, MA) secondary antibody 
(1:7500) was used for detection. Plasma western blots were performed by diluting plasma 1:120 
in Laemmli sample loading buffer and proceeding as above. 
 
Mass Spectrometry 
Samples were spotted (0.1 µL/spot) on the MALDI target, and calibrated with the peptide 
calibration mixture 4700 (ABSciex, Concord, ON, Canada). The matrix used was α-Cyano-4-
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hydroxycinnamic acid. Samples were analyzed using the Reflector Positive Ion Mode within a 
mass range of 800-4000 m/z. Spectra were collected using an ABSciex 5800 MALDI-TOF/TOF 
housed in the UNC Proteomics Core Facility. Spectra were analyzed using Data Explorer v4.5 
(Applied Biosystems).  
Statistical Analysis 
Comparison of two groups was performed using Student's t-test. Comparison of three or 
more groups was performed using one- or two-way analysis of variance, as appropriate, and the 
Student-Newman-Keuls post hoc test. Data are displayed as mean ± standard error of the 
mean. If data failed to indicate a normal distribution, non-parametric Mann-Whitney test was 
used to compare means. p <0.05 confers statistical significance. All calculations were 
performed using GraphPad Prism 7.0 software (La Jolla, CA). 
 
3.4 Results 
Deficiency of FXII or FXI does not protect against APAP–induced acute liver injury 
To determine if FXII deficiency affects in vivo thrombin generation in a mouse model of APAP-
induced acute liver injury, we measured plasma levels of TAT complexes. Consistent with 
previous publications, plasma TAT levels increased at 6 and 24 hours after APAP administration 
in wild-type (FXII+/+) mice compared to saline-treated animals (Figure 3.1A). A similar increase 
was observed in FXII deficient (FXII-/-) mice at both time points, indicating that FXII does not 
significantly contribute to thrombin generation in this model (Figure 3.1A). Since FXII is known 
to exert proinflammatory effects independently of its procoagulant activity (41), we analyzed the 
effect of FXII deficiency on liver injury. Compared to saline-treated mice, plasma levels of 
alanine aminotransferase (ALT) were significantly increased at 6 and 24 hours after APAP 
administration in FXII+/+ mice; however, FXII deficiency had no effect on ALT levels (Figure 
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3.1B). Furthermore, liver sections were evaluated using a histopathological scoring system 
(Supplemental Table 1) in which reviewers were blinded to genotype. Consistent with the 
absence of any effect of FXII deficiency on plasma levels of ALT in APAP-challenged mice, no 
significant difference between FXII+/+ or FXII-/- mice was observed in any of these parameters, 
at either time point (Figure 3.1C, D).  
Thrombin is known to activate FXI independently of FXIIa (42). To determine if thrombin-
dependent feed-back activation of FXI enhances thrombin generation in a mouse model of ALF, 
we examined the effect of FXI deficiency on plasma TAT levels in APAP-challenged mice. FXI 
deficiency had no significant effect on plasma TAT levels at 6 or at 24 hours (Supplemental 
Figure 3.1A). Similar to FXII–deficient animals, there was no significant difference in plasma 
levels of ALT between FXI+/+ and FXI-/- mice at 6 or 24 hours after APAP injection 
(Supplemental Figure 3.1B). Histological analysis demonstrated that FXI deficiency had no 
effect on hepatocyte necrosis or lesion size (Supplemental Figure 3.1C, D).  
 
High molecular weight kininogen but not plasma prekallikrein deficiency ameliorates 
hepatocellular injury induced by APAP 
FXIIa not only activates FXI but also activates PK, which in turn cleaves HK. HK is not 
enzymatically active, but functions as a cofactor for FXI and PK activation, such that HK 
deficiency can blunt contact-mediated thrombin generation (43). HK is also the precursor of the 
pro-inflammatory and vasodilatory molecule, BK. Consistent with our observations in FXII-/- 
mice, there was no significant difference in plasma TAT or ALT levels between PK+/+ and PK-/- 
animals at 24 hours after APAP exposure (Supplemental Figure 3.2A and B). Histological 
analysis confirmed that there were no substantial differences in liver injury indices between 
PK+/+ and PK-/- mice (Supplemental Figure 3.2C and D). Interestingly however, despite the 
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lack of a significant effect on APAP-induced thrombin generation measured by plasma TAT 
levels (Figure 3.2A), plasma levels of ALT were significantly reduced in HK-/- mice compared to 
HK+/+ animals at both 6 and 24 hours after APAP administration (Figure 3.2B). Together, these 
data suggest that HK contributes to APAP-induced liver injury independently of thrombin 
generation or activation by PKa. 
Histologic analysis also revealed a statistically significant reduction of APAP-induced 
liver injury in HK-/- mice at 24 hours. In HK+/+ mice, hydropic degeneration was more 
noticeable at 6 hours, in addition to significantly larger necrotic zones, and more bridging 
necrosis at 24 hours. Quantification of necrotic areas at 24 hours showed that HK-/- mice 
exhibited a mean necrotic area of 30.4%, while the area of liver necrosis for APAP-challenged 
HK+/+ animals’ was 42.2%, p=.0009 (Figure 3.2C and D). A significant reduction in neutrophil 
numbers in the livers of HK-/- mice 24-hours after APAP overdose was also observed (Figure 
3.3A, B). High -dose acetaminophen results in generation of the reactive metabolite N-acetyl-p -
benzoquinoneimine, which can be neutralized by glutathione stores. The differences observed 
in HK-/- and HK+/+ animals could not be attributed to differences in APAP metabolism, as 
indicated by glutathione consumption at 2 hours (Supplemental Figure 3.3). Given these 
findings, we also assayed circulating levels of interleukin 6 (IL-6), a pleiotropic immune cytokine 
indicative of generalized inflammation. HK-/- animals had significantly less circulating IL-6 at 24 
hours following APAP toxicity (Figure 3.3C). 
 
Plasmin cleaves HK to release bradykinin in vitro and ex vivo 
Canonical cleavage of HK by PKa generates bioactive HK fragments and the 
inflammatory peptide BK (44). Lack of protection against APAP-induced ALF observed in PK-/- 
mice, together with strong attenuation of liver injury demonstrated in HK-/- mice, suggested that 
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HK is cleaved independently of PKa in this situation. It has been reported that HK can also be 
cleaved by plasmin in a buffer system (17). We therefore examined whether cleavage of plasma 
HK by plasmin occurs ex vivo. Mouse plasma was treated with either 116.5 µg/mL mouse 
plasmin, 200 µg/mL kaolin (a clay mineral that specifically activates FXII and subsequently PK), 
or saline vehicle, and incubated for one hour. Western blotting analysis demonstrated efficient 
cleavage of HK in both plasmin- and kaolin-treated plasma, although these two pathways 
produced fragments with different migration patterns (Figure 3.4A, left panel). Notably, plasmin-
mediated cleavage of HK was independent of PK (Figure 3.4A, mid panel) or FXII (Figure 3.4A 
right panel), whereas kaolin-initiated cleavage required both proteins. Moreover, plasmas from 
normal (Figure 3.4B left panel), PK-deficient (Figure 3.4B mid panel), or FXII-deficient (Figure 
3.4B right panel) human subjects also exhibited HK cleavage by plasmin, while kaolin only 
initiated cleavage of HK in normal control plasma, indicative of the absolute need for FXII.  
To determine if plasmin-mediated cleavage of HK results in the release of BK, 
recombinant human HK, at normal physiological concentrations (80 µg/mL), was exposed to 
various concentrations of human plasmin or PKa for one hour, and BK generation was assayed 
by ELISA (Figure 3.5A). Both plasmin and PKa led to the release of BK. Plasmin-mediated 
cleavage of HK plateaued at concentrations > 60 µg/mL, whereas concentration-dependent 
PKa-mediated cleavage was observed over the entire concentration range (Figure 3.5A). While 
the BK ELISA is widely accepted for quantification, it is possible that other peptides containing 
the BK sequence were detected, given that the assay contains a single antibody (and detection 
of epitopes often requires a minimum of 5-8 amino acids) (45). Therefore, we used mass 
spectrometry to identify peptide fragments following enzymatic processing of HK. The BK 
standard was calculated at 1060.6 m/z (Figure 3.5B). No BK peptide was detected in the 
purified HK sample (Figure 3.5C). Cleavage of HK by PKa produced a predominant peptide 
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mass of 1060.4 m/z (Figure 3.5D). Similarly, HK cleavage by plasmin also produced a major 
peptide mass of 1060.4 m/z, indicating BK generation (Figure 3.5E). 
 
Bradykinin signaling has no effect on APAP-induced acute liver injury  
Incubation of wild type mouse plasma ex vivo with plasmin resulted in BK generation, 
although the levels of BK were lower compared to those observed in mouse plasma activated 
by kaolin (Supplemental Figure 3.4A). Moreover, plasmin-mediated generation of BK was 
observed in FXII-deficient plasma, suggesting BK production did not require a CS. Together, 
these data demonstrate that plasmin-mediated cleavage of HK results in the release of BK and 
generation of HK fragments in a buffer system as well as in plasma. These data are consistent 
with the observations that the fibrinolytic system can drive BK production (46,47). To assess if 
BK contributed to liver injury in the APAP toxicity model, we used a pharmacological inhibitor of 
the bradykinin receptor 2, bradyzide, as well as mice deficient in the bradykinin 2 receptor alone 
(BKr 2) or both the bradykinin 1 and 2 receptors (BKr 1,2). Mice receiving bradyzide exhibited 
no difference in liver injury as indicated by ALT levels in plasma (Supplemental Figure 3.4B). 
Furthermore, deletion of BKr 2 alone (Supplemental Figure 3.4C) or both BKr 1 and 2 
(Supplemental Figure 3.4D) failed to protect mice from APAP-induced liver injury. Collectively, 
these data indicate that although plasmin is capable of cleaving HK to produce BK, BK is not a 
mediator of the early phase of APAP-induced liver injury.  
 
Reconstitution of HK restores liver injury in APAP-challenged HK-/- mice. 
Other domains of HK beyond BK have been demonstrated to have biological activity 
(44). Our findings with BK inhibition and BK receptor deficiency demonstrated that an alternative 
mechanism was responsible for the reduced injury in HK-/- mice. To confirm that protection in 
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the HK-/- mice was specifically due to the absence of HK, we reconstituted HK-/- mice with 
human kininogen (hHK) at physiological levels prior to APAP challenge. Animals restored with 
hHK exhibited a significant increase in circulating ALT above that seen in HK-/- mice (Figure 
3.6A). Two-color Western blotting was performed to confirm that hHK was circulating in mouse 
plasma at the time of tissue collection (Figure 3.6B). Together, these data strongly suggest that 
a product of HK cleavage, other than BK, is responsible for liver injury. 
 
Plasminogen deficiency prevents HK cleavage in the liver of APAP-challenged mice 
In vitro studies demonstrated that plasmin can generate HK cleavage products. 
However, we had yet to associate HK cleavage with liver injury. Activation of the fibrinolytic 
system has been previously demonstrated in mice challenged with APAP, and plasminogen 
deficiency has been reported to provide significant protection in this model (16). Consistent with 
these observations, plasma concentrations of active tPA (Supplemental Figure 3.5A) and 
plasmin anti-plasmin (PAP) complexes (Supplemental Figure 3.5B) were significantly elevated 
at 6 and 24 hours following APAP administration in mice. Knowing that the 6-hour time point 
likely had the highest level of plasmin activity, Western blot analysis was conducted on liver 
homogenates to assess HK cleavage. We observed a cleaved HK product of MW ~56 kDa 
(Supplemental Figure 3.6A) in the livers of APAP-treated mice, whereas this fragment was not 
detected in saline-treated controls.  
To ascertain if plasmin could cleave HK in vivo, we challenged plasminogen sufficient 
(PLG+/+), deficient (PLG-/-), and heterozygous (PLG+/-) mice with APAP and assessed HK 
cleavage and hepatocellular injury. Western blot revealed HK cleavage in PLG+/+ mice, which 
was reduced in PLG+/- mice and absent in PLG-/- mice (Figure 3.6C). Moreover, plasminogen 
deficiency significantly reduced APAP-induced liver injury, indicated by a reduction in serum 
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ALT activity (Figure 3.6D). In aggregate, these data suggest that an HK cleavage product 
resulting from plasmin activity contributes to APAP hepatotoxicity. 
Fibrinolytic activation and kininogen cleavage in human ALF patients.  
Our data in APAP-challenged mice prompted us to determine whether plasmin 
generation and HK cleavage are increased in patients with ALF caused by APAP overdose. 
Plasma ALT activity and PAP complexes were increased in ALF patients (Figure 3.7A-B), and in 
agreement with prior studies (48), tPA-mediated clot lysis time (CLT) was also prolonged 
(Figure 3.7C), indicating consumption of plasminogen. To determine if HK cleavage is 
detectable in plasma from ALF patients, we performed ELISAs specific for intact or cleaved HK 
in plasma. ALF patients exhibited a significantly reduced concentration of circulating intact HK 
(Figure 3.7D), accompanied by a significant increase in cleaved HK (Figure 3.7E) compared to 
healthy controls. Plasma samples were also analyzed for activation of FXII, FXI, and PK by 
measuring concentrations of FXIIa, FXa, or PKa complexed with C1 esterase inhibitor (C1). No 
significant difference was observed in the levels of FXIIa:C1 or PKa:C1 whereas plasma levels 
of FXIa:C1 were reduced (Supplemental Table 3.2). Corroborating observations from the animal 
model, these results demonstrate enhanced plasmin generation and HK cleavage in the 
absence of CS activation in humans with ALF caused by APAP overdose. 
 
3.5 Discussion 
Activation of coagulation is a prominent feature of experimental APAP-induced liver 
injury. Several animal studies have demonstrated that thrombin contributes to the early phase of 
the injury (11-13,49). The activation of coagulation during APAP-induced liver injury is initiated 
by de-encryption of procoagulant properties of tissue factor expressed by hepatocytes (50). In 
contrast to the major contribution of the extrinsic coagulation pathway, the findings presented 
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here documented that deficiency of FXII or FXI had no significant effect on either thrombin 
generation or hepatotoxicity in APAP-challenged mice. Moreover, activation of FXII and FXI, 
measured by plasma levels of active enzyme:C1 complexes, was not increased in the cohort of 
patients suffering from APAP-induced liver failure. Collectively, these results support the 
conclusion that the extrinsic, but not intrinsic coagulation, pathway predominantly drives the 
coagulation-mediated pathologies associated with APAP-induced hepatic injury in mice.  
It is widely accepted that FXIIa-dependent generation of PKa leads to HK cleavage (41). 
In addition, it has been proposed that PKa generated independently of FXIIa can also cleave HK 
(51,52). Interestingly, we observed that a reduction in APAP-induced liver injury observed in 
HK-/- mice was not mirrored by a similar protection in FXII-/- or PK-/- mice. These data strongly 
suggest that the contribution of HK to the liver pathology in this model is independent of the 
upstream components of the CS. In addition to PKa, several other enzymes have been shown 
to cleave HK in buffer systems (53-55). Among these other proteases, plasmin has been shown 
to directly cleave HK (18), as well as prime HK for subsequent cleavage by PKa (17). Our data 
demonstrate that (i) plasmin can efficiently cleave HK in a purified system and plasma, with the 
subsequent release of BK and HK fragments, and (ii) there is a failure of HK cleavage in APAP-
challenged plasminogen-deficient mice. Importantly, these findings establish for first time that 
plasmin cleavage of HK does occur in vivo and identify a setting where this specific proteolytic 
event promotes a downstream pathological outcome. 
Plasmin is a serine protease that degrades the fibrin network within clots. It is generated 
by tPA- or uPA-mediated proteolysis of plasminogen, a protein predominantly synthesized in the 
liver. It has been previously shown that circulating plasmin activity increases during acute liver 
injury (56-58). Deficiency of plasminogen activator inhibitor-1, the principal inhibitor of tPA, 
exacerbates liver injury in APAP-challenged mice (16,59). Importantly, inhibition of plasmin or 
genetic deficiency of plasminogen also attenuates hepatotoxicity in mice after APAP overdose 
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(12,59). However, the mechanism of this protection has been unknown. Recent studies 
demonstrated that plasmin mediates liver injury, in part via degradation of the extracellular 
matrix and subsequent disruption of hepatic sinusoidal vascular integrity (16). Furthermore, 
plasmin-mediated activation of Kupffer cells may contribute to upregulation of proinflammatory 
cytokine expression during the early phase of APAP-induced liver injury in mice (60). However, 
given the protection from APAP-induced liver toxicity observed in plasminogen-deficient mice or 
in mice receiving tranexamic acid (an inhibitor of plasmin generation) (12), it is very likely that 
multiple, non-overlapping pathways mediate the pathologic effects of plasmin. Results from our 
study indicate that in addition to the mentioned mechanisms (16,60), plasmin-dependent 
cleavage of HK is an entirely novel mechanism linking the fibrinolytic system with exacerbated 
hepatotoxicity.  
Limited data exist regarding the production and function of BK in acute liver injury (61-
63). Our in vivo findings using bradyzide or BK receptor knockout mice reveal no contribution of 
BK signaling to acute APAP-induced liver injury. However, in vitro studies have demonstrated 
that HK fragments are responsible for cytokine release from mononuclear cells (64), endothelial 
cell apoptosis (65), and modulation of neutrophil activity (66). These observations are consistent 
with the reduced intra-hepatic neutrophil infiltration and reduction of plasma IL-6 levels that we 
observed in HK-/- mice after APAP challenge. In aggregate, our data support the hypothesis 
that HK fragments other than BK contribute to APAP-induced inflammation.  
To summarize, our study indicates that HK contributes to APAP-induced acute liver 
injury independently of thrombin generation and activation of the CS. Instead, we showed that 
activation of the fibrinolytic system with subsequent plasmin generation mediates HK cleavage 
in APAP-challenged mice. The results of this study and others suggest that interruption of 
plasmin generation and subsequent HK cleavage, for example by the use of tranexamic acid or 
by supplementation with α2-antiplasmin, may be protective in this form of acute liver injury (12). 
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Identification of cleaved HK in human patients may also support future studies investigating the 
role of HK in ALF sequelae such as hepatic encephalopathy. Thus, while BK had no apparent 
role in mediating acute liver parenchymal injury, it is possible that BK generation may contribute 
to of blood brain barrier dysfunction, complicating ALF (47). Moreover, BK antagonists have 
been used to block dynamic hemodynamic instability (67), a condition that is frequently present 











Figure 3.1: FXII deficiency does not protect against APAP toxicity. A) Plasma 
concentration of thrombin – antithrombin complexes (TAT) at 6 and 24 hours post APAP 
administration. B) Plasma alanine aminotransferase (ALT) activity. C) Histological scoring of 
liver pathology. D) Representative photomicrographs of liver histology from FXII+/+ and FXII-/- 
mice at 24 hours following APAP treatment, 40x magnification. N = 18-19 mice per group, 
combined from three independent experiments. Saline samples collected at 24-hour time 








Figure 3.2: HK deficiency does not inhibit coagulation activation, but does ameliorate 
APAP-induced hepatotoxicity. A) Plasma concentration of thrombin–antithrombin (TAT) 
complexes at 6 and 24 hours post APAP administration. B) Plasma alanine aminotransferase 
(ALT) activity. C) Percentage of necrotic area, average of five 40x fields per mouse. D) 
Representative photomicrographs of liver histology from HK+/+ and HK-/- animals at 24 hours 
following APAP treatment, 40x magnification. N = 26-30 mice per group, combined from six 
independent experiments. Saline samples collected at 24-hour time point (N = 9-10 mice per 
group). Error bars represent standard error of the mean. * = p <0.05 versus HK+/+; ** = p <0.01; 






Figure 3.3: Neutrophil recruitment and inflammation are blunted in HK-deficient mice. 
A) Representative photomicrographs from HK+/+ and HK-/- APAP–treated mice, 40x 
magnification; staining represents neutrophil infiltration in the liver. B) Quantification of 
neutrophils per field, average of three 40x fields per mouse. C) Plasma concentration of 
interleukin-6. N = 22-25 mice per group, combined from five independent experiments. Error 






Figure 3.4: Plasmin cleaves kininogen independent of contact system activation. A) 
Western blot of plasma HK in wild-type, PK-/-, and FXII-/- mice. Green = polyclonal antibody 
against FXI and PK –binding domain within the light chain of HK. Cleavage products of 
kininogen are shown following the addition of vehicle (saline +2% glycerol), plasmin 
(116.5µg/mL), or kaolin (200µg/mL) for 1 hour. B) Western blot of human plasma HK in a 
normal, PK-deficient, and FXII-deficient patient. Green = polyclonal antibody against the light 
chain of human HK. Cleavage products of HK are shown following the addition of vehicle 





Figure 3.5: Plasmin cleaves kininogen to release bradykinin in buffer. A) Concentration 
of bradykinin released in an enzymatic buffer system, measured by ELISA. 80µg/mL HK was 
incubated for one hour with either kallikrein or plasmin at indicated concentrations. Error bars 
represent standard deviation from the mean. B) Mass spectra of bradykinin standard 
(250µg/mL). C) Mass spectra of purified HK (800µg/mL). D) Mass spectra of HK incubated 
with kallikrein (150µg/mL) for one hour. E) Mass spectra of HK incubated with plasmin 








Figure 3.6: Kininogen presence exacerbates liver injury, and plasminogen presence 
correlates with its cleavage in situ. A) Circulating levels of ALT in plasmas from HK-
sufficient (HK+/+), HK -deficient (HK-/-), and HK -deficient animals reconstituted with human 
kininogen (HK-/- + hHK). N= 6 mice per group. Error bars represent standard error of the mean. 
B) Western blot of plasma kininogen in deficient, reconstituted, and sufficient mice. Green = 
polyclonal antibody against the light chain of human HK. Red = polyclonal antibody against 
the FXI and PK–binding domain within the light chain of mouse HK. Arrow indicates full length 
HK. C) Western blot of mouse liver homogenate following APAP exposure. Green = polyclonal 
antibody against the FXI and PK–binding domain within the light chain of mouse HK. 
Plasminogen (PLG) knockout (-/-), heterozygous (+/-), and wild-type (+/+), and vehicle (saline) 
animals are grouped in panels on the same membrane. Arrow indicates cleaved HK. D) 
Plasma levels of ALT in mice 24 hours after APAP exposure. N = 3 mice per group. Error bars 







Figure 3.7: Activation of fibrinolysis and cleavage of kininogen in human acute liver 
failure patient plasma. A) Plasma ALT activity. B) Circulating concentration of plasmin-α2 
antiplasmin (PAP) complexes. C) tPA-mediated clot lysis time. Longer times indicate reduced 
fibrinolytic capacity. D) Plasma concentration of intact HK. E) Plasma concentration of cleaved 
HK. N =8 normal controls, 67 with ALF. Bars represent the sample mean. * = p <0.05; ** = p 
<0.01; **** = p <0.0001. 
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0 Normal-no evidence of necrotic progression  
1 Hydropic degeneration Hepatocyte loss and necrosis: 1-3 layers 
2 
Hepatocyte loss and necrosis: 3-5 layers 
<1/2 affected lobules exhibit bridging necrosis  
Central vein endothelial damage 
3 
Hepatocyte loss and necrosis: >5 layers 
>1/2 affected lobules exhibit bridging necrosis 
Sinusoidal congestion with red blood cells 
Inflammatory infiltrate beyond necrotic zone 
4 
Massive hepatocyte loss extending from central vein to 
portal area 
Hemorrhage extending beyond necrotic zone 
  
 
Supplemental Table 3.1: Histopathological scoring criteria. Injury score was calculated 
based on the layers of affected hepatocytes as counted from the central veins, as well as 









Supplemental Figure 3.1: FXI deficiency does not protect against APAP toxicity. A) 
Plasma concentration of thrombin–antithrombin complexes (TAT) at 6 and 24 hours post 
APAP administration. B) Plasma alanine aminotransferase (ALT) activity. C) Histological 
scoring of liver pathology. D) Representative photomicrographs of liver histology from FXI+/+ 
and FXI-/- mice at 24 hours following APAP treatment, 40x magnification. N = 12-13 mice per 
group, combined from two independent experiments. Saline samples collected at 24-hour time 








Supplemental Figure 3.2: PK deficiency does not protect against APAP toxicity. A) 
Plasma concentration of thrombin–antithrombin complexes (TAT) at 24 hours post APAP 
administration. B) Plasma alanine aminotransferase (ALT) activity. C) Histological scoring of 
liver pathology. D) Representative photomicrographs of liver histology from PK+/+ and PK-/- 
mice at 24 hours following APAP treatment, 40x magnification. n= 11-13 mice per group, 
combined from two independent experiments. Saline samples collected at 24-hour time point 








Supplemental Figure 3.3: Genetic deficiency of HK does not affect APAP metabolism. 
Glutathione (GSH) was measured in liver homogenate two hours after APAP exposure. Error 
bars represent standard deviation from the mean. No significant differences were observed 
between HK+/+ and HK -/- mice. N = 6 mice per group, and 3 saline vehicle mice were used as 








Supplemental Figure 3.4: Bradykinin production in plasma is not limited to contact 
activation, but has no effect in APAP liver injury. A) Concentration of bradykinin following 
ex vivo activation of plasma from wild-type or FXII-/- mice using vehicle (saline +2% glycerol), 
plasmin (116.5µg/mL), or kaolin (200µg/mL) for 1 hour. B) Circulating ALT in mice 
administered bradyzide 2 mg/kg in saline, or vehicle prior to APAP exposure. N = 14-15 mice. 
C) Plasma ALT levels in wild-type, or mice deficient in bradykinin receptor 2 (BKr2). N = 10-
12 mice. D) Plasma ALT levels in wild-type, or mice deficient in both bradykinin receptors 1 
and 2 (BKr 1,2) N = 11-12 mice. Error bars represent standard error of the mean. * = p <0.05; 









Supplemental Figure 3.5: Activation of fibrinolysis in acetaminophen–induced acute 
liver injury. A) Plasma concentration of active tissue plasminogen activator (tPA) at indicated 
time points following APAP administration. B) Plasma concentration of plasmin-α2 antiplasmin 
complexes (PAP) at indicated time points. Results of two combined independent experiments. 
N= 12-14 mice per group. Saline samples collected at 24-hour time point (N = 5 mice). Error 





Supplemental Figure 3.6: Kininogen cleavage in situ following APAP dosing and 
plasmin activity. A) Western blot of liver homogenate at 6 hours after APAP administration. 
Green = polyclonal antibody against the FXI and PK–binding domain within the light chain of 
mouse HK. Cleavage products of kininogen can be seen between 64 and 49 kDa, as indicated 
by arrow. B) Circulating concentration of plasmin-α2 antiplasmin complexes (PAP) in HK-
sufficient and HK-deficient mice at 6 and 24 hours after APAP dosing. N = 12 mice per group, 
and 6 saline vehicle-treated mice were used as an assay control. Error bars represent standard 
error of the mean. * = p <0.05. A significant difference was observed between HK+/+ and HK -







Control ALF P value 
FXIa:C1 (nM) 0.26 ± 0.01 0.22 ± 0.02 <0.0001 
FXIIa:C1 (nM) 0.90 ± 0.08 6.25 ± 11.6 0.2032 
PKa:C1 (nM) 9.77 ± 2.6 12.31 ± 6.5 0.2846 
 
Supplemental Table 3.2: Activation of FXII, FXI, and PK in acute liver failure patient 
samples. Concentrations of FXIIa, FXa, or PKa complexed with C1 esterase inhibitor (C1) 
detected in human plasma. No significant difference was observed in the levels of FXIIa:C1 or 




1. Stravitz RT, Kramer DJ. Management of acute liver failure. Nat Rev Gastroenterol Hepatol. 
2009;6(9):542-553. 
2. Budnitz DS, Lovegrove MC, Crosby AE. Emergency department visits for overdoses of 
acetaminophen-containing products. Am J Prev Med. 2011;40(6):585-592. 
3. Jollow DJ, Mitchell JR, Potter WZ, Davis DC, Gillette JR, Brodie BB. Acetaminophen-
induced hepatic necrosis. II. Role of covalent binding in vivo. J Pharmacol Exp Ther. 
1973;187(1):195-202. 
4. Mitchell JR, Jollow DJ, Potter WZ, Davis DC, Gillette JR, Brodie BB. Acetaminophen-
induced hepatic necrosis. I. Role of drug metabolism. J Pharmacol Exp Ther. 1973;187(1):185-
194. 
5. Mitchell JR, Jollow DJ, Potter WZ, Gillette JR, Brodie BB. Acetaminophen-induced hepatic 
necrosis. IV. Protective role of glutathione. J Pharmacol Exp Ther. 1973;187(1):211-217. 
6. Potter WZ, Davis DC, Mitchell JR, Jollow DJ, Gillette JR, Brodie BB. Acetaminophen-
induced hepatic necrosis. 3. Cytochrome P-450-mediated covalent binding in vitro. J Pharmacol 
Exp Ther. 1973;187(1):203-210. 
7. Nelson SD. Molecular mechanisms of the hepatotoxicity caused by acetaminophen. Semin 
Liver Dis. 1990;10(4):267-278. 
8. Jaeschke H, Bajt ML. Intracellular signaling mechanisms of acetaminophen-induced liver 
cell death. Toxicol Sci. 2006;89(1):31-41. 
9. Jaeschke H, Knight TR, Bajt ML. The role of oxidant stress and reactive nitrogen species in 
acetaminophen hepatotoxicity. Toxicol Lett. 2003;144(3):279-288. 
10. Jaeschke H, Xie Y, McGill MR. Acetaminophen-induced Liver Injury: from Animal Models to 
Humans. J Clin Transl Hepatol. 2014;2(3):153-161. 
11. Ganey PE, Luyendyk JP, Newport SW, et al. Role of the coagulation system in 
acetaminophen-induced hepatotoxicity in mice. Hepatology. 2007;46(4):1177-1186. 
12. Sullivan BP, Kassel KM, Jone A, Flick MJ, Luyendyk JP. Fibrin(ogen)-independent role of 
plasminogen activators in acetaminophen-induced liver injury. Am J Pathol. 2012;180(6):2321-
2329. 
13. Miyakawa K, Joshi N, Sullivan BP, et al. Platelets and protease-activated receptor-4 
contribute to acetaminophen-induced liver injury in mice. Blood. 2015;126(15):1835-1843. 
14. Kopec AK, Joshi N, Cline-Fedewa H, et al. Fibrin(ogen) drives repair after acetaminophen-
induced liver injury via leukocyte alphaMbeta2 integrin-dependent upregulation of Mmp12. J 
Hepatol. 2017;66(4):787-797. 
15. Ilich A, Bokarev I, Key NS. Global assays of fibrinolysis. Int J Lab Hematol. 2017;39(5):441-
447. 
16. Gao S, Silasi-Mansat R, Behar M, Lupu F, Griffin CT. Excessive plasmin compromises 
hepatic sinusoidal vascular integrity after acetaminophen overdose. Hepatology. 2018. 
94 
 
17. Kleniewski J, Blankenship DT, Cardin AD, Donaldson V. Mechanism of enhanced kinin 
release from high molecular weight kininogen by plasma kallikrein after its exposure to plasmin. 
J Lab Clin Med. 1992;120(1):129-139. 
18. Kleniewski J, Donaldson VH, Wagner CJ. Plasmin induced changes in high molecular 
weight kininogen (HMW-K). Adv Exp Med Biol. 1983;156:165-173. 
19. Cap AP. Plasmin: a driver of hemovascular dysfunction. Blood. 2016;128(20):2375-2376. 
20. Maas C, Renne T. Coagulation factor XII in thrombosis and inflammation. Blood. 
2018;131(17):1903-1909. 
21. Key NS. Epidemiologic and clinical data linking factors XI and XII to thrombosis. 
Hematology Am Soc Hematol Educ Program. 2014;2014(1):66-70. 
22. Ratnoff OD, Margolius A, Jr. Hageman trait: an asymptomatic disorder of blood coagulation. 
Trans Assoc Am Physicians. 1955;68:149-154. 
23. Rosenthal RL, Dreskin OH, Rosenthal N. New hemophilia-like disease caused by 
deficiency of a third plasma thromboplastin factor. Proc Soc Exp Biol Med. 1953;82(1):171-174. 
24. Gailani D, Renne T. The intrinsic pathway of coagulation: a target for treating 
thromboembolic disease? J Thromb Haemost. 2007;5(6):1106-1112. 
25. Worm M, Kohler EC, Panda R, et al. The factor XIIa blocking antibody 3F7: a safe 
anticoagulant with anti-inflammatory activities. Ann Transl Med. 2015;3(17):247. 
26. Stravitz RT, Ellerbe C, Durkalski V, et al. Bleeding complications in acute liver failure. 
Hepatology. 2018;67(5):1931-1942. 
27. Reuben A, Tillman H, Fontana RJ, et al. Outcomes in Adults With Acute Liver Failure 
Between 1998 and 2013: An Observational Cohort Study. Ann Intern Med. 2016;164(11):724-
732. 
28. Ganger DR, Rule J, Rakela J, et al. Acute Liver Failure of Indeterminate Etiology: A 
Comprehensive Systematic Approach by An Expert Committee to Establish Causality. Am J 
Gastroenterol. 2018;113(9):1319-1328. 
29. Pauer HU, Renne T, Hemmerlein B, et al. Targeted deletion of murine coagulation factor XII 
gene-a model for contact phase activation in vivo. Thromb Haemost. 2004;92(3):503-508. 
30. Gailani D, Lasky NM, Broze GJ, Jr. A murine model of factor XI deficiency. Blood Coagul 
Fibrinolysis. 1997;8(2):134-144. 
31. Stavrou EX, Fang C, Merkulova A, et al. Reduced thrombosis in Klkb1-/- mice is mediated 
by increased Mas receptor, prostacyclin, Sirt1, and KLF4 and decreased tissue factor. Blood. 
2015;125(4):710-719. 
32. Merkulov S, Zhang WM, Komar AA, et al. Deletion of murine kininogen gene 1 (mKng1) 
causes loss of plasma kininogen and delays thrombosis. Blood. 2008;111(3):1274-1281. 
33. Bugge TH, Flick MJ, Daugherty CC, Degen JL. Plasminogen deficiency causes severe 




34. Institute of Laboratory Animal Resources (U.S.). Committee on Care and Use of Laboratory 
Animals. Guide for the care and use of laboratory animals. NIH publication. Bethesda, Md.: U.S. 
Dept. of Health and Human Services, Public Health Service:v. 
35. Buntrock RE. Sax's dangerous properties of industrial materials. Choice: Current Reviews 
for Academic Libraries. 2013;51(1):109-109. 
36. Yamamoto-Imoto H, Zamolodchikov D, Chen ZL, et al. A novel detection method of cleaved 
plasma high-molecular-weight kininogen reveals its correlation with Alzheimer's pathology and 
cognitive impairment. Alzheimers Dement (Amst). 2018;10:480-489. 
37. Henderson MS, E; Noubouossie, D; Mailer, R; Renne, T; McCrae, K;, Key, N; Pawlinski, R. 
High Molecular Weight Kininogen but Not Factor XII Deficiency Attenuates Acetaminophen-
Induced Liver Injury in Mice. American Society of Hematology 61st Annual Meeting and 
Exposition. Blood Coagulation and Fibrinolytic Factors: Poster III Orlando, FL, USA; 2019. 
38. Ilich A, Noubouossie DF, Henderson M, et al. Development and application of global 
assays of hyper- and hypofibrinolysis. Res Pract Thromb Haemost. 2020;4(1):46-53. 
39. Lu Y, Zhang C, Chen YH, et al. Immature mice are more susceptible than adult mice to 
acetaminophen-induced acute liver injury. Sci Rep. 2017;7:42736. 
40. Merkulov S, Zhang WM, Komar AA, et al. Deletion of murine kininogen gene 1 (mKng1) 
causes loss of plasma kininogen and delays thrombosis. Blood. 2008;111(3):1274-1281. 
41. Renne T, Schmaier AH, Nickel KF, Blomback M, Maas C. In vivo roles of factor XII. Blood. 
2012;120(22):4296-4303. 
42. Gailani D, Broze GJ, Jr. Factor XI activation in a revised model of blood coagulation. 
Science. 1991;253(5022):909-912. 
43. Saito H, Ratnoff OD, Waldmann R, Abraham JP. Fitzgerald Trait: Deficiency of a Hitherto 
Unrecognized Agent, Fitzgerald Factor, Participating in Surface-Mediated Reactions of Clotting, 
Fibrinolysis, Generation of Kinins, and the Property of Diluted Plasma Enhancing Vascular 
Permeability (PF/Dil). J Clin Invest. 1975;55(5):1082-1089. 
44. Sainz IM, Pixley RA, Colman RW. Fifty years of research on the plasma kallikrein-kinin 
system: from protein structure and function to cell biology and in-vivo pathophysiology. Thromb 
Haemost. 2007;98(1):77-83. 
45. Hebbes TR, Turner CH, Thorne AW, Crane-Robinson C. A "minimal epitope" anti-protein 
antibody that recognises a single modified amino acid. Mol Immunol. 1989;26(9):865-873. 
46. Back N, Guth PS, Munson AE. On the relationship between plasmin and kinin. Ann N Y 
Acad Sci. 1963;104:53-68. 
47. Marcos-Contreras OA, Martinez de Lizarrondo S, Bardou I, et al. Hyperfibrinolysis 
increases blood-brain barrier permeability by a plasmin- and bradykinin-dependent mechanism. 
Blood. 2016;128(20):2423-2434. 
48. Lisman T, Bakhtiari K, Adelmeijer J, Meijers JC, Porte RJ, Stravitz RT. Intact thrombin 
generation and decreased fibrinolytic capacity in patients with acute liver injury or acute liver 
failure. J Thromb Haemost. 2012;10(7):1312-1319. 
96 
 
49. Groeneveld D, Cline-Fedewa H, Baker KS, et al. Von Willebrand factor delays liver repair 
after acetaminophen-induced acute liver injury in mice. J Hepatol. 2020;72(1):146-155. 
50. Kopec AK, Luyendyk JP. Coagulation in liver toxicity and disease: role of hepatocyte tissue 
factor. Thromb Res. 2014;133 Suppl 1:S57-59. 
51. Schmaier AH, McCrae KR. The plasma kallikrein-kinin system: its evolution from contact 
activation. J Thromb Haemost. 2007;5(12):2323-2329. 
52. Shariat-Madar Z, Mahdi F, Schmaier AH. Identification and characterization of 
prolylcarboxypeptidase as an endothelial cell prekallikrein activator. J Biol Chem. 
2002;277(20):17962-17969. 
53. Higashiyama S, Ishiguro H, Ohkubo I, Fujimoto S, Matsuda T, Sasaki M. Kinin release from 
kininogens by calpains. Life Sci. 1986;39(18):1639-1644. 
54. Dobo J, Major B, Kekesi KA, et al. Cleavage of kininogen and subsequent bradykinin 
release by the complement component: mannose-binding lectin-associated serine protease 
(MASP)-1. PLoS One. 2011;6(5):e20036. 
55. Kleniewski J, Donaldson V. Granulocyte elastase cleaves human high molecular weight 
kininogen and destroys its clot-promoting activity. J Exp Med. 1988;167(6):1895-1907. 
56. Tomiya T, Hayashi S, Ogata I, Fujiwara K. Plasma alpha 2-plasmin inhibitor-plasmin 
complex and FDP-D-Dimer in fulminant hepatic failure. Thromb Res. 1989;53(3):253-260. 
57. Pernambuco JR, Hughes RD, Langley PG, Izumi S, Williams R. Hepatocyte growth factor 
and plasminogen activation in fulminant hepatic failure. Blood Coagul Fibrinolysis. 
1994;5(4):511-515. 
58. Pernambuco JR, Langley PG, Hughes RD, Izumi S, Williams R. Activation of the fibrinolytic 
system in patients with fulminant liver failure. Hepatology. 1993;18(6):1350-1356. 
59. Pant A, Kopec AK, Baker KS, Cline-Fedewa H, Lawrence DA, Luyendyk JP. Plasminogen 
Activator Inhibitor-1 Reduces Tissue-Type Plasminogen Activator-Dependent Fibrinolysis and 
Intrahepatic Hemorrhage in Experimental Acetaminophen Overdose. Am J Pathol. 
2018;188(5):1204-1212. 
60. Roth K, Strickland J, Joshi N, et al. Dichotomous Role of Plasmin in Regulation of 
Macrophage Function after Acetaminophen Overdose. Am J Pathol. 2019;189(10):1986-2001. 
61. Bekheet SH, Awadalla EA, Salman MM, Hassan MK. Bradykinin potentiating factor isolated 
from Buthus occitanus venom has a protective effect against cadmium-induced rat liver and 
kidney damage. Tissue Cell. 2011;43(6):337-343. 
62. Doria C, Elia ES, Kang Y, et al. Acute hypotensive transfusion reaction during liver 
transplantation in a patient on angiotensin converting enzyme inhibitors from low 
aminopeptidase P activity. Liver Transpl. 2008;14(5):684-687. 
63. Betto MR, Lazarotto LF, Watanabe TT, Driemeier D, Leite CE, Campos MM. Effects of 
treatment with enalapril on hepatotoxicity induced by acetaminophen in mice. Naunyn 
Schmiedebergs Arch Pharmacol. 2012;385(9):933-943. 
97 
 
64. Khan MM, Bradford HN, Isordia-Salas I, et al. High-molecular-weight kininogen fragments 
stimulate the secretion of cytokines and chemokines through uPAR, Mac-1, and gC1qR in 
monocytes. Arterioscler Thromb Vasc Biol. 2006;26(10):2260-2266. 
65. Wang S, Hasham MG, Isordia-Salas I, Tsygankov AY, Colman RW, Guo YL. Upregulation 
of Cdc2 and cyclin A during apoptosis of endothelial cells induced by cleaved high-molecular-
weight kininogen. Am J Physiol Heart Circ Physiol. 2003;284(6):H1917-1923. 
66. Wachtfogel YT, DeLa Cadena RA, Kunapuli SP, et al. High molecular weight kininogen 
binds to Mac-1 on neutrophils by its heavy chain (domain 3) and its light chain (domain 5). J Biol 
Chem. 1994;269(30):19307-19312. 
67. Barratt-Due A, Johansen HT, Sokolov A, et al. The role of bradykinin and the effect of the 
bradykinin receptor antagonist icatibant in porcine sepsis. Shock. 2011;36(5):517-523. 














CHAPTER 4: INFLUENCE OF KININOGEN IN OTHER PATHOLOGIES 
4.1 Overview 
If questioned about disease states mediated by HK, hereditary angioedema is the 
classic recollection (1). Hereditary angioedema results from increased HK cleavage and BK 
release, that results in attacks of severe swelling. However, HK has been implicated in multiple 
disease states, including arthritis (2), inflammatory bowel disease (3,4), and Alzheimer’s 
disease (5). Current research suggests that the CS is likely more involved in certain 
coagulation-linked pathologies than previously thought.  
Transfusion associated circulatory overload (TACO) is a transfusion -related reaction 
that can occur after a rapid transfusion of a large blood volume. TACO symptoms include 
edema, hypertension, and dyspnea. Transfusion -related acute lung injury (TRALI) similarly 
occurs rapidly which presents as hypotension, acute respiratory distress, and cyanosis. 
Transfusion- related complications have been linked to BK activity (6), but no mechanism has 
been elucidated. 
Sickle cell disease is a red blood cell disorder caused by abnormal polymerization of 
hemoglobin, the oxygen carrying protein (7). It has been demonstrated in animal models that 
inhibition of coagulation greatly improves survival, as well as other disease complications such 
as pulmonary hypertension and cardiac hypertrophy/remodeling (8). Our research aims to 
improve outcomes in human sickle cell disease, without increasing bleeding risk. Therefore, 
inhibition of the CS offers an attractive therapeutic target. 
Multiple sclerosis, and its mouse model experimental autoimmune encephalitis, are 
diseases where the blood brain barrier (BBB) is disrupted, and immune cells and plasma 
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proteins interact with the central nervous system. Activation of coagulation within the brain and 
spinal cord causes an inflammatory response and immune activation (9). While extrinsic 
coagulation and fibrinolysis are the subjects of ongoing research, the role of the CS has not 
been explored.  
 
4.2 Microvesicles 
Storage lesion-induced red cell-derived microvesicles (RBC-MVs) propagate coagulation 
by supporting the assembly of the prothrombinase complex. It has also been reported that RBC-
MVs initiate coagulation via the intrinsic pathway (10). To elucidate the mechanism(s) of RBC-
MV-induced coagulation activation, the ability of storage lesion-induced RBC-MVs to activate 
each zymogen of the intrinsic pathway was assessed in a buffer system. Simultaneously, the 
thrombin generation (TG) assay was used to assess their ability to initiate coagulation in 
plasma. RBC-MVs directly activated FXII or PK, but not FXI or FIX. RBC-MVs initiated TG in 
normal pooled plasma and in FXII-deficient or FXI-deficient, but not in FIX-deficient plasma, 
suggesting an alternate pathway that bypasses both FXII and FXI. Interestingly, RBC-MVs 
generated FIXa in a PK-dependent manner. Similarly, purified PKa -activated FIX in buffer and 
initiated TG in normal pooled plasma, as well as FXII-deficient or FXI-deficient, but not FIX-
deficient plasma. Dual inhibition of FXIIa by CTI and kallikrein by SBTI was required to abolish 
RBC-MV-induced TG in normal pooled plasma, whereas PKa inhibition alone was sufficient to 
abolish TG in FXII-deficient or FXI-deficient plasma. Heating RBC-MVs at 60°C for 15 minutes 
or pre-treatment with trypsin abolished TG, suggesting the presence of microvesicle-associated 
protein(s) that is(are) required for contact activation. In summary, RBC-MVs activate both FXII 
and PK, leading to FIX activation by two independent pathways, namely the canonical FXIIa-
FXIa-FIX pathway and via direct PKa activation of FIX. These data suggest novel mechanisms 
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by which RBC transfusion mediates inflammatory and/or thrombotic outcomes such as TACO or 
TRALI. 
4.3 Methods 
Isolation and characterization of RBC-MVs 
Aliquots of RBC concentrates were transferred into 50-mL plastic conical tubes and 
centrifuged twice at 2500 g for 15 minutes each, as recommended by the International Society 
on Thrombosis and Haemostasis (11). Dynamic light scattering was used to confirm that 
isolated RBC-MVs contained only submicron MVs before nanoparticle tracking analysis (NTA) 
was used for precise sizing and enumeration. RBC-MVs were pelleted by centrifugation at 




TG assays were performed as previously described (12), with some modifications. In 
brief, 20 µL buffer, kaolin, human PKa, or washed RBC-MVs were added to 80 µL of MV-free 
plasma in a black 96-well microplate. Then, 20 µL of a solution containing 90 mM CaCl2, 2.496 
mM Z-Gly-Gly-Arg-AMC fluorogenic thrombin substrate. and 2.4 μM synthetic lipid vesicles 
dissolved in 20 mM N-2-hydroxyethylpiperazine-N′-2-ethanesulfonic acid–buffered saline was 
added. Substrate hydrolysis was monitored over time in a Biotek Synergy H1M fluorometer. TG 






Factor IX activation assay 
FIXa generation was assessed by measuring the concentration of FIXa-AT, by using our 
in-house sandwich enzyme-linked immunosorbent assay (ELISA) that captures FIXa and 
detects AT (detailed methods in Chapter 2.3). RBC-MVs were incubated for 150 minutes at 
37°C with 100nM purified human factor IX with 580nM PK and 670nM HK. Following this AT 
and 4U/mL heparin was added to the reaction.  
 
4.4 Results 
RBC-MVs were resuspended in recalcified MV-free plasma deficient in FXII, FXI, or FIX. 
In the absence of RBC-MVs, no TG was detected in any of these factor-deficient plasmas after 
recalcification and supplementation with 4 µM synthetic lipid vesicles. When compared with 
normal plasma, TG induced by RBC-MVs in FXII- or FXI-deficient plasma was delayed and 
reduced, but not abolished (Figure 4.1) 
Thus, we added CTI or SBTI alone or in combination with NPP to block FXIIa or PKa, 
respectively. CTI abolished kaolin-initiated TG, whereas SBTI had little effect, indicating that the 
PKa-FIX pathway does not play a major role in TG initiated by kaolin (Figure 4.2A) 
The pattern of thrombin inhibition was different when TG was initiated by RBC-MVs 
when compared with kaolin. CTI alone delayed and attenuated TG induced by RBC-MVs in MV-
free NPP (Figure 4.2B) in a manner similar to FXII (Figure 4.2C) or FXI (Figure 4.2D) deficiency. 
These results are consistent with a partial contribution of the canonical (FXII/FXI-dependent) 
intrinsic pathway to TG induced by RBC-MVs in plasma. SBTI alone also delayed and 
attenuated RBC-MV–induced TG in NPP (Figure 4.2B). However, RBC-MV–induced TG was 
completely abolished in the presence of both CTI- and SBTI in NPP (Figure 4.2B), confirming 
that TG is dependent on both FXIIa and PKa generation. Interestingly, SBTI alone abolished TG 
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induced by RBC-MVs in FXII-deficient (Figure 4.2C) or FXI-deficient (Figure 4.2D) plasma, 
indicating that the PKa-FIX pathway by itself can lead to robust TG. In aggregate, these data 
strongly support the existence of 2 independent pathways for initiation of TG in plasma after 
contact activation by RBC-MVs. 
We next assessed whether RBC-MVs can indirectly activate FIX via PK activation in 
buffer. Kaolin, RBC-MVs, or buffer were incubated with FIX in the presence of PK and its 
cofactor, HK. FIX activation was detected by measuring FIXa-AT complexes. (Figure 4.3). 
Kaolin and RBC-MVs promoted the formation of levels of FIXa-AT complexes that were 
(respectively) five- and fourfold greater than the buffer control (Figure 4.3). Levels of FIXa-AT 
were not greater than the buffer control when RBC-MVs were incubated with FIX and HK in the 
absence of PK, indicating the dependence on PK activation. These results strongly support the 
PKa-FIX pathway as an alternative to the canonical intrinsic pathway for coagulation activation 










Figure 4.1: Reduction of thrombin generation in intrinsic enzyme-deficient plasma. Y 
axis represents the rate of TG (IIa) per second, over assay time (X axis). Plasma deficient 
(def) in the coagulation factors compared to normal pooled plasma (NPP). RBC-MVs = 
microvesicles collected from stored red blood cell transfusion units. Def-IX sample (blue solid 









Figure 4.2: Effect of corn trypsin inhibitor (CTI) and soybean trypsin inhibitor (SBTI) on 
thrombin generation initiated by red cell concentrate microvesicles (RBC-MVs) in 
plasma. A): Effect of CTI (hashed green) and SBTI (hashed grey) on kaolin-initiated (30µg/mL) 
thrombin generation in MV-free normal pool plasma (NPP). B): Effect of CTI (hashed green) 
and SBTI (grey) on thrombin generation initiated by RBC-MVs in NPP. C): Effect of SBTI (grey) 
on thrombin generation initiated by RBC-MVs in FXII-deficient MV-free plasma as compared 
to XII-deficient plasma alone (hashed dark green). D): Effect of SBTI (grey) on thrombin 
generation initiated by RBC-MVs in FXI-deficient MV-free plasma as compared to XI-deficient 
plasma alone (hashed dark purple). Data representative of 3 independent experiments. Buffer 
(blue) was used as negative control (A-D), and normal pool plasma (NPP, red) was used as a 








Figure 4.3: Factor IXa-AT complexes formed after interaction with red cell concentrate 
microvesicles (RBC-MVs). Kaolin was used as positive control (purple bar). Buffer was used 
as negative control (B-F; blue). FIXa-AT was measured using an in-house ELISA capturing 
FIX and detecting AT. PK = prekallikrein. Data expressed as mean +/-SD of at least 3 
independent experiment run in duplicates. ***= p < 0.001. p < 0.05 is considered significant. 
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4.5 Sickle cell disease 
Sickle cell disease (SCD) is characterized by chronic hemolytic anemia, vaso-occlusive 
crises, chronic inflammation, and activation of coagulation. The clinical complications such as 
painful crisis, stroke, pulmonary hypertension, nephropathy and venous thromboembolism lead 
to cumulative organ damage and premature death (13,14). We hypothesize that HK contributes 
to the hypercoagulable and pro-inflammatory state that leads to these complications. Decreased 
levels of FXII, PK, and HK have been reported in the plasma of sickle cell patients compared to 
healthy controls, indicating an increased consumption of these factors due to activation of CS 
(15,16). Since HK plays a central role for both the intrinsic coagulation and the CS, we 
hypothesized that HK activation may contribute to the pathological consequences of SCD. We 
found elevated plasma levels of cleaved HK in sickle patients compared to healthy controls, 




The study was approved by the University of North Carolina’s Institutional Review Board 
for human subjects. We recruited 54 African American outpatients with SCD and 23 healthy 
African American controls. Inclusion criteria were that patients were in steady state (at least 1 
month from last pain crisis), had not received blood products within 3 months, and were not on 
oral contraceptive, anticoagulant, or antiplatelet therapy. Blood samples were obtained by clean 
venipuncture using a 21G butterfly needle and the first 3 mL were discarded. Platelet-poor 





Detection of cleaved HK in patient samples.  
To detect changes in HK and cHK in human plasma using a sandwich ELISA, we used a 
capture antibody able to detect both HK and cHK (3E8), and two detection antibodies specific 
for intact HK (2B7) or cHK (4B12) as previously described (17). Antibodies were biotinylated 
using EZ-Link® Sulfo-NHS-LC-Biotin according to the manufacturer's instructions. Nunc 
Maxisorp plates were coated with capture antibody 3E8 (500 ng/well) in sodium bicarbonate 
buffer overnight at 4°C. Plasma was thawed at 37°C for 8 minutes prior to analysis of cHK and 
iHK; the samples had not previously undergone any freeze-thaw cycles. Plasma samples were 
diluted at 1:500 and 1:1000 using Hank’s balanced salt solution with 1% BSA prior to loading, 
and incubated for 60 min at room temperature. After washing, biotinylated 2B7 or 4B12 were 
added to replicate wells to detect intact HK (iHK) or cHK, respectively, and incubated for 60 min 
at RT. After washing, horseradish peroxidase-conjugated streptavidin was added to all wells 
according to manufacturer specifications. After a final wash, color was developed by adding 
3,3′,5,5′-Tetramethylbenzidine (TMB) substrate for 30 min at RT, and the reaction was stopped 




Cleavage of kininogen is increased in sickle cell patients 
We determined levels of cHK in the plasma samples of sickle patients and healthy 
controls by ELISA as previously described (17). We found that the levels of cHK were 
significantly increased in sickle cell patient samples (Figure 4.4A), whereas levels of total intact 
HK (iHK) were not different between the two groups (Figure 4.4B). Moreover, the ratio of 
cHK/iHK was also elevated in SCD patient plasma (Figure 4.4C). These data suggest that there 
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is likely a chronic state of CS activation, leading to cleavage of HK, in SCD. Future studies are 
necessary to determine if this HK cleavage contributes to the chronic inflammation and other 














Figure 4.4: Status of high molecular weight kininogen (HK) in sickle cell disease (SCD) 
patients at steady state. Concentration of HK isoform in patient plasma samples. AA = 
normal hemoglobin, SS = hemoglobin/SCD patients. A) cHK = cleaved kininogen. B) iHK = 
intact HK. C) the calculated ratio of cHK by iHK. HbAA (n=23) and HbSS (n=54) Data are 
presented as mean ± SD.*= p < 0.05, considered significant. 
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4.8 Experimental autoimmune encephalitis 
Multiple sclerosis (MS) is the most common immune-mediated disorder of the central 
nervous system (CNS), affecting over 400,000 Americans (18). MS is an inflammatory 
demyelinating disease; whereby immune cells cross the blood-brain barrier (BBB) to the CNS 
and destroy the insulating component of nerve cells. This destruction disrupts axonal 
transmission and slows or blocks nervous communication, which results in a range of clinical 
manifestations from proprioceptive, to physical, and mental difficulties in patients. Experimental 
allergic encephalomyelitis (EAE) is the animal model which evaluates the inflammatory 
mechanisms of MS (19). EAE is typically induced by immunization with spinal homogenate, 
myelin proteins, or myelin peptides to prime the immune system. 
These inflammation-associated lesions were noted for their distribution around the 
vasculature over 150 years ago (20).  These findings prompted the investigation of coagulation 
in multiple sclerosis. The terminal enzyme of the coagulation cascade, thrombin, is a serine 
protease that cleaves the plasma protein fibrinogen to form fibrin matrices, the structural 
component of a thrombus. Venular thrombi were characterized in sclerotic plaques over 80 
years ago (21). Early research into the benefits of anticoagulation using dicoumarin 
demonstrated no recurrence symptoms in 23 of 27 patients with the relapsing-remitting form of 
the disease, yet some bleeding complications were present (22).  
Modern studies have demonstrated that thrombin generation in patients with the 
relapsing-remitting form is significantly greater than that of normal controls (23). Moreover, 
reports have shown elevated plasma levels of the coagulation factors prothrombin and Factor X 
in patients with relapsing–remitting MS, but not in plasma samples from patients with primary 
progressive MS (24). Proteomic studies from patient samples revealed accumulation of 
coagulation proteins within CNS lesions (25). Animal studies have demonstrated fibrin 
deposition within lesions at the onset of EAE (26), and in a coagulation-driven driven model of 
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EAE introduction of fibrinogen induced immune recruitment to the CNS (27). Together, these 
findings indicate that activation of coagulation can contribute to the neuroinflammatory response 
in MS, offering an alternative target for pharmacotherapy. However, as bleeding into the CNS 
has high morbidity, inhibition of intrinsic coagulation may provide benefit without the same 
bleeding risk.  
 
4.9 Methods 
Induction and clinical evaluation of EAE 
To induce of EAE, mice were immunized with Hooke kits (EK-0115) according to the 
instruction. Briefly, mice received a s.c. injection on flanks of 0.1 ml MOG-CFA emulsion was 
injected to the flanks of each mouse (0.2 ml/animal). 2 hours later, each mouse received an i.p. 
injection of 200ng pertussis toxin in 0.1 ml of PBS. A second injection of pertussis toxin (200 ng 
per mouse) was given 24 later. Mice were examined every day for signs of EAE and scored 0–5 
according to the recommendations of Stromnes and Goverman (2006) (28) as follows: 0 = 
unaffected, 0.5 = partial limp tail, 1 = paralyzed tail, 1.5 = loss in coordinated movements, 2 = 
hind limb paresis, 2.5 = one hind limb paralyzed, 3 = both hind limbs paralyzed, 3.5 = hind limbs 
paralyzed and weakness in forelimbs, 4 = one forelimb paralyzed, 4.5 = both forelimbs 
paralyzed, and 5 = moribund/death. Mice displaying a score of 2 or higher received daily 
manual bladder evacuation, and those with a score >3.5 received daily subcutaneous injections 
of sterile saline. Mice were killed by exsanguination and decapitation under anesthesia, or by 






All statistical analyses were performed using GraphPad Prism (version 8.4). Data are 
represented as mean ±S.E.M unless specifically indicated in the text. For two-group comparison 
of continuous data, a two-tailed Student’s t-test was used. For multiple-group comparison, data 
were analyzed by one- or two-way ANOVA followed by Bonferroni multiple comparisons. Log-




To study the role of HK in multiple sclerosis we induced EAE in knockout mice (HK-/-) 
and in wild type controls (HK+/+). The penetrance of EAE was 100% in both groups of mice, yet 
deficiency of HK did not affect the time of the EAE onset (Figure 4.5). At day 13, the mean 
clinical score for HK-/- mice was 2.2, while HK+/+ was 2.9. There were no significant differences 
from day 15 to day 18. However, mean clinical score in the subgroup HK-/- mice was reduced 
from day 19 until the end of experiment on day 30. These data suggest that HK is detrimental in 
EAE. More studies are needed, to determine if this protection is mediated by activation of the 
CS, or the fibrinolytic pathway and plasmin -mediated cleavage of HK. While activation of the 















Figure 4.5: Status of high molecular weight kininogen (HK) in sickle cell disease (SCD) 
patients at steady state. Concentration of HK isoform in patient plasma samples. AA = 
normal hemoglobin, SS = hemoglobin/SCD patients. A) cHK = cleaved kininogen. B) iHK = 
intact HK. C) the calculated ratio of cHK by iHK. HbAA (n=23) and HbSS (n=54) Data are 
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CHAPTER 5: SUMMARY AND FUTURE DIRECTIONS 
5.1 Summary and future directions 
Traditional anticoagulants inhibit enzymes in the common pathway of coagulation. 
However, even with precise dosing, and regular patient evaluation, bleeding is not uncommon. 
The intrinsic coagulation pathway is therefore an attractive pharmacological target, as inhibition 
of FXIIa, the initiating intrinsic enzyme, has no effect on hemostasis. However, FXII is not 
responsible for only activating FXI, and intrinsic coagulation alone. PK, and its activated form 
PKa create a positive feedback loop with FXII as part of the CS. These two enzymatic pathways 
are linked not only by FXIIa, but share a common cofactor in HK, which facilitates localization of 
FXI and/or PK to the same surface which activated FXII. 
Research into the functional domains of HK (1), including BK (2), has revealed a 
multitude of potential physiological effects caused by this protein. However, there has been 
limited investigation into which enzymes can actually cleave HK. Plasmin has been 
demonstrated to cleave HK (3,4), yet limited research exists on if functionality of those domains 
exists, or is altered, following plasmin cleavage. Recent research suggests activation of 
fibrinolysis, rather than contact activation is responsible for inflammation, and potential BBB 
disruption (5-7). This finding was of great interest to us given that in APAP-induced ALF, those 
patients exhibit the most rapid signs of coagulopathy and hepatic encephalopathy. 
The mouse model of APAP -induced liver injury has been well studied; though hepatic 
encephalopathy in mice is debated (8), the pathology is primarily analogous to human disease. 
Recently, inhibition of coagulation has shown to be protective during the injurious phase (9) of 
the mouse model. Our hypothesis was that inhibition of intrinsic coagulation in the mouse model 
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would also limit disease severity, while maintaining hemostasis. In addition to assaying the 
effects of APAP toxicity in mice deficient in the proteins of the CS, we analyzed human ALF 
samples for evidence of contact activation and HK cleavage. Our data demonstrate that genetic 
deletion of FXII, FXI, and PK conferred no protection in the mouse model of ALF. Surprisingly 
deletion of HK was hepatoprotective, independent of thrombin generation, within the first 24 
hours. However, independent studies have demonstrated that PLG deficiency, and lack of 
plasmin activity is protective in APAP toxicity (10,11). Our studies were the first to demonstrate 
that HK can be cleaved by plasmin to produce BK, though BK signaling was not protective 
within the first 24 hours of the APAP model. Moreover, analysis of a human ALF patient cohort 
demonstrated that there was significantly elevated cleaved HK, while PKa activation was not. 
Moreover, these human patients exhibited substantial activation of fibrinolysis, to the extent that 
little-to-no ex vivo plasmin activity could be detected in clot dissolution assays.  
We have initiated studies in SCD, MS/EAE, and transfusion complications to determine 
the effects of HK cleavage in each. Yet, our data suggest that we should not only consider 
contact activation driving HK cleavage, but plasmin as well. Future studies will be necessary to 
determine where plasmin cleaves HK, and if other domain functionality is altered. We aspire to 
collect plasmas from patients receiving massive transfusion with and without TRALI or TACO, 
and analyze those samples for HK cleavage. Currently, there is no assay for detecting cleaved 
HK in animal samples. If funding permitted, I would strive to develop this assay in mice, as it is a 
critically unmet need. Lastly, as there are ALF models which better capitulate hepatic 
encephalopathy (12), I would determine if plasmin or HK was necessary for development of this 
complication, or similarly hepatoprotective.  
In conclusion, while our initial hypothesis was not substantiated, we identified a novel 
mechanism of BK production, which provides further evidence for the inflammatory aspects of 
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fibrinolysis (6). I have greatly enjoyed my time with Drs. Key and Pawlinski. I have been shown 
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